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DObjectives: In cyanotic patients undergoing repair of heart defects, chronic hypoxia is thought to lead to greater
susceptibility to ischemia and reoxygenation injury. We sought to find an explanation to such a hypothesis by
investigating the cardiac gene expression in patients with tetralogy of Fallot undergoing cardiac surgery.
Methods: The myocardial gene profile was investigated in right ventricular biopsy specimens obtained from 20
patients with a diagnosis of cyanotic (n ¼ 11) or acyanotic (n¼ 9) tetralogy of Fallot undergoing surgical repair.
Oligonucleotide microarray analyses were performed on the samples, and the array results were validated with
Western blotting and enzyme-linked immunosorbent assay.
Results: Data revealed 795 differentially expressed genes in cyanotic versus acyanotic hearts, with 198 upregu-
lated and 597 downregulated. Growth/morphogenesis, remodeling, and apoptosis emerged as dominant func-
tional themes for the upregulated genes and included the apoptotic gene TRAIL (tumor necrosis factor–related
apoptosis-inducing ligand), the remodeling factor OPN (osteopontin), and the mitochondrial function gene
COX11 (cytochrome-c oxidase 11). In contrast, transcription, mitogen-activated protein kinase signaling, and
contractile machinery were the dominant functional classes for the downregulated genes, which included the
calcium-handling geneNCX1 (sodium-calcium exchanger). Protein levels of COX11, NCX1, OPN, and LYZ (ly-
sozyme) in the myocardium followed the same pattern obtained by means of transcriptomics. The TRAIL level
did not change in myocardium but increased in circulating blood of cyanotic patients, suggesting the myocardium
as a possible source. Additionally, our data showed increased protein expression of apoptosis markers in cyanotic
myocardium.
Conclusions: Chronic hypoxia in cyanotic children with tetralogy of Fallot induced the expression of genes as-
sociated with apoptosis and remodeling and reduced the expression of genes associated with myocardium con-
tractility and function. (J Thorac Cardiovasc Surg 2010;140:337-45)Supplemental material is available online.
Cyanotic pediatric patients undergoing cardiac surgery are
exposed to a chronic hypoxic state that can reduce their anti-
oxidant reserve capacity, leading to a greater susceptibility to
the oxidative stress of ischemia and reperfusion at the time of
surgical correction.1-3 Our group has shown that cyanotic
children have worse myocardial reperfusion injury and
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The Journal of Thoracic and Casimilar periods of ischemic cardioplegic arrest.4 We have
also shown that reintroduction of high oxygen levels to cya-
notic patients undergoing cardiopulmonary bypass (CPB)
leads to myocardial damage before ischemic cardioplegic
arrest.5 Our results suggest that the injury seen after cardio-
plegic arrest might in part be due to CPB-induced reoxygena-
tion injury, and this has also been demonstrated in previous
studies.6
Several recent studies have used microarray technology to
examine the global myocardial stress response during car-
diac surgery, focusing on the human congenitally mal-
formed hearts.7-10 Kaynak and colleagues7 examined gene
expression profiles in patients with tetralogy of Fallot
(TOF), ventricular septal defect, and right ventricular hyper-
trophy (RVH) compared with profiles seen in those with nor-
mal hearts. Another investigation examined gene expression
changes in patients with cyanotic TOF in comparison with
those seen in patients with normal hearts and showed that
the upregulation of genes encoding vascular endothelial
growth factor (VEGF) and extracellular matrix proteins are
the key events contributing to RVH and stunted angiogene-
sis in patients with TOF.10 Konstantinov and associates8 ex-
amined the gene expression profiles in children undergoingrdiovascular Surgery c Volume 140, Number 2 337
TABLE 1. Baseline patients’ characteristics and clinical outcomes
Cyanotic
patients
(n ¼ 11)
Acyanotic
patients
(n ¼ 9)
P
value
Age (mo) 10.6  5.5 9.5  2.3 .1
Weight (kg) 8.04  1.7 8.01  1.0 .7
RVOT velocity (m/s) 4.6  0.4 4.4  0.7 .2
RV wall indexed (mm/m2) 16.6  3.0 17.1  1.9 .1
VSD size (mm) 9.9  1.3 9.8  1.6 .1
Use of preoperative b-blockers 4 1 .05
Preoperative O2 saturation (%) 79.6  7.5 94.2  3.5 .01
Crossclamp time (min) 78.0  15.6 73.0  20.7 .1
CPB time (min) 132.0  29.0 90.2  17.7 .05
In-hospital mortality 0 0
Inotropic support
(minimal/significant)
1/10 7/2 .01
Inotropic duration (h) 54 (42–136) 22 (12–29) .03
Total mg dopamine/kg (3 103) 16.3 (12.2–36.3) 5.2 (1.9–7.3) .01
Postoperative ventilation time (h) 42 (24–77) 18 (5–33) .01
Postoperative ICU stay (h) 87 (49–122) 40 (26–48) .001
Postoperative hospital stay (d) 11 (9–12) 7 (5–9) .05
Data are presented as means  standard deviations or medians (interquartile ranges).
RVOT, Right ventricular outflow tract; RV, right ventricular; VSD, Ventricular septal
defect; ICU, intensive care unit.
Abbreviations and Acronyms
BAX ¼ Bcl-2-associated X protein
CPB ¼ cardiopulmonary bypass
ELISA ¼ enzyme-linked immunosorbent assay
ERK ¼ extracellular signal-regulated kinase
FDR ¼ false discovery rate
MAPK ¼ mitogen-activated protein kinase
RVH ¼ right ventricular hypertrophy
TOF ¼ tetralogy of Fallot
VEGF ¼ vascular endothelial growth factor
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Dcardiac surgery for right heart obstructive lesions, including
TOF, and showed that neonatal myocardium has a unique
pattern of gene expression dominated by genes with cardio-
protective, antihypertrophic, and antiproliferative proper-
ties, reflecting a stress-induced protective program.
However, to our knowledge, no previous genome-wide
investigation has beenmade to determine the global gene ex-
pression profiles associated with chronic hypoxia in patients
with TOF. The aim of this study was therefore to investigate
the global ventricular myocardial gene expression profiles of
cyanotic and acyanotic patients with a diagnosis of TOF un-
dergoing corrective cardiac surgery.
MATERIALS AND METHODS
Twenty patientswith a diagnosis of cyanotic (n¼ 11) or acyanotic (n¼ 9)
TOF undergoing surgical repair at the Bristol Royal Hospital for Children
were studied. All patients were in stable condition without preoperative re-
spiratory or inotropic support. Preoperative characteristics in the 2 groups
are summarized in Table 1. Patients with cyanotic TOF presented with sev-
eral episodes of spells and repeated saturation measurements of less than
90% (mean, 79.6%  7.5%), whereas patients with acyanotic TOF did
not have a history of cyanotic spells and presentedwith saturations of greater
than 90% (mean, 94.2%  3.5%). Preoperative echocardiographic data
showed significant gradient across the right ventricular outflow tract in
both groups. The studywas approved by the hospital research ethics commit-
tee, and parental informed consent was gained for all patients. Intraoperative
anesthetic and operative techniques were standardized, as previously re-
ported.4 After the operation, all patients were admitted to the pediatric inten-
sive care unit and were managed according to unit protocols.4,5
Postoperative inotropic support was considered to be either minimal (do-
pamine 5 kg1 $ min1 for 24 hours) or significant (dopamine>5 mg $
kg1 $min1 with or without other inotropic agents, such as adrenaline, nor-
adrenaline, or milrinone). Decisions regarding inotropic support and venti-
lation were based on hemodynamic status (eg, low mixed venous saturation
and high lactic acidosis) and clinical judgment.4,5
Cardiac Muscle Biopsy Specimens
Ventricular biopsy specimens (10 mg net weight) were collected from
the apex of the right ventricle by using a ‘‘Trucut’’ needle4 immediately af-
ter institution of CPB. Each specimen was immediately put in RNA Later
solution (Qiagen, Crawley, United Kingdom) and kept overnight at 4C.
The next day, RNA Later solution was removed, and biopsy specimens
were kept at80C until RNA extraction.
The concentration of total RNA samples was assessed by means of spec-
trophotometry (Nanodrop, Wilmington, Del) and was further analyzed for338 The Journal of Thoracic and Cardiovascular Surgintegrity with a Bioanalyzer 2100 with RNA 6000 Nano Assay (Agilent
Technologies, Stockport, United Kingdom).
Gene Microarrays: Data Analysis
Ventricular total RNAs (1 mg) from individual patients were processed as
previously described.11 Raw data (CEL files) were uploaded into ArrayStar
software version 2.1 (DNASTAR, Inc,Madison,Wis) for normalization and
statistical analysis. The robust multichip analysis algorithm was used for
background correction, quantile normalization, and median polish summa-
rization. The statistical analysis was carried out with ArrayStar software. A
Student’s t test and Benjamini and Hochberg multiple testing corrections for
false discovery rate (FDR) were used. The FDR-adjusted P value was set to
less than .05, and transcripts were filtered on the basis of 1.8-fold or greater
difference.
Functional Annotation and Network Analysis
Differentially expressedgeneswere analyzedaccording topredefinedpath-
ways and functional categories annotated by Kyoto Encyclopedia of Genes
and Genomes and Gene Ontology by using the Database for Annotation, Vi-
sualization, and Integrated Discovery bioinformatics resource.12 For an over-
represented Gene Ontology or Kyoto Encyclopedia of Genes and Genomes
pathway, cutoff P values of .01 and .05 have been selected for the downregu-
lated and upregulated genes, respectively. For Tables E1 and E2, all gene
annotations were checked by using online tools and databases: Entrez Gene
(www.ncbi.nlm.nih.gov/sites/entrez). The software PathwayStudio
(Ariadne, Rockville, Md) and the ResNet database were used to explore the
networks of interactions in which the physiologically regulated genes are
potentially involved.
Immunohistochemistry and Western Blotting
Right ventricular specimens were fixed in 4% paraformaldehyde,
washed in PBS, and embedded in paraffin, and 4-mm sections were
obtained. Immunohistochemistry was performed with the ABC-Kit from
DakoCytomation (Glostrup, Denmark). Photos were taken at 403
magnification.ery c August 2010
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DWestern blotting was performed as previously described.13 Statistical
analysis (unpaired t test) was carried out with Instat 3 software (GraphPad
Software, Inc, La Jolla, Calif), and a P value was calculated for comparison.
Enzyme-Linked Immunosorbent Assay Protein
Analysis
Blood was collected from all patients before surgical intervention, and
plasma was separated and stored at80C. Human TRAIL levels were mea-
sured in plasma samples by using the Diaclone enzyme-linked immunosor-
bent assay (ELISA) kit. Each sample was performed in duplicate. Statistical
analysis (unpaired t test) was carried out with Instat 3 software, and a P
value was calculated for comparison.Statistical Analysis
For the clinical data, continuous variables were summarized by using
means and standard deviations (or medians and interquartiles range if the
distribution was skewed), and categorical data were summarized as numbers
and percentages. Differences between groups were compared by using the
c2 test for categorical variables and the t or Wilcoxon rank sum tests, as ap-
propriate, for continuous variables.RESULTS
Clinical data are summarized inTable 1. The 2 groupswere
comparable in terms of age, weight, and crossclamp time.
There were no deaths and nomajor morbidity in both groups.
One patient in the cyanotic group required a pacemaker but
regained sinus rhythm at follow-up. One patient in the acya-
notic group required another run of CPB to resect more mus-
cle from the right ventricular outflow tract after the first
procedure. Echocardiographic analysis at discharge did not
show any significant residual gradient across the right ven-
tricular outflow tract (mean velocity<3 m/s in both groups)
or residual ventricular septal defects. CPB time was longer
in the cyanotic group, who required more extensive trans-
annular patching and reconstruction of the pulmonary artery
compared with the acyanotic patients. Cyanotic patients had
longer inotropic support, ventilation time, and intensive care
and hospital stays compared with the acyanotic group.FIGURE 1. Enrichment analysis of functional groups within the genes dif-
ferentially expressed in cyanotic compared with acyanotic patients. A, Pie
chart of the regulated genes in cyanotic compared with acyanotic patients
(1.8-fold). Three quarters of the genes were downregulated and a quarter
were upregulated. B and C, Selected GO annotations of genes upregulated
(B) and downregulated (C) in cyanotic patients. The histograms show the
distribution of these annotations.Gene Microarray Analysis
Analysis of differentially expressed genes. We have used
the Affymetrix GeneChip Human Genome U133 Plus 2.0
Array in this study because it represents themost comprehen-
sive whole human genome expression array, providing
coverage of more than 47,000 well-substantiated human
genes (www.affymetrix.com). Of the genes examined, 795
were identified as differentially expressed in cyanotic
versus acyanotic heart biopsy specimens (P< .05, t test
followed by Benjamini and Hochberg FDR correction),
with 198 (25%) upregulated and 597 (75%)
downregulated by more than 1.8-fold (Figure 1, A, and
Tables E1 and E2). Genes identified as upregulated or
downregulated beyond 1.8-fold unmasked overrepresented
biologic process in each gene set (Figure 1, B and C). Myo-
cardial contractility and function, as identified by means ofThe Journal of Thoracic and Cacell adhesion, cytoskeletal organization, transcription regu-
lation, guanosine triphosphatase signal transduction,
mitogen-activated protein kinase (MAPK) signaling, andrdiovascular Surgery c Volume 140, Number 2 339
FIGURE 2. Biological association network of the significantly upregulated genes (>1.8-fold) of cyanotic versus acyanotic patient comparisons. The asso-
ciation between the network entities were based on available PubMed citations. Each node in the network map is linked to an html page showing the protein
annotation based on available public databases. Small square boxes connecting 2 nodes are linked to an html page showing the type of effect (positive or
negative) and the supporting Medline references.
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hearts (Figure 1, C). Upregulated transcripts functionally
overrepresented apoptosis, cell movement, morphogenesis,
and development (Figure 1, B). Collectively, these changes
indicate genetic remodeling of the cyanotic myocardium in
response to chronic hypoxia.
Pathway analysis. Using Pathway Studio software (Ari-
adne), we further analyzed the differentially expressed genes
(cyanotic vs acyanotic). The analysis looked for the direct
pathways connecting genes. For the upregulated genes, the
resulting biological association networks are presented in
Figure 2. Interestingly, the upregulated genes spanned al-
most all the cellular organelles. Analysis of downregulated
genes associated with the ontological ‘‘regulation of tran-
scription’’ and ‘‘MAPK signaling pathway’’ classes were
composed of 83 and 23 downregulated genes, respectively.
Of these, 38 and 18 genes, respectively, integrated into direct
biological association networks (Figure 3), whereas 45 and 5
genes did not possess interactions.
Cyanosis increases growth, morphogenesis, and remod-
eling processes and apoptosis signaling. Increased ex-
pression of growth, morphogenesis, and remodeling
signaling genes emerged as a dominant functional theme
for the upregulated genes. This was evident by the increased
expression levels of the growth signaling factors FGF7,
TGFBR2, EGFR, and insulin-like growth factor binding pro-340 The Journal of Thoracic and Cardiovascular Surgtein 7 and the remodeling factors SPP1 (OPN) and ACTL6A
(Table E1 and Figure 2).
Another dominant functional theme for the upregulated
genes was apoptosis. Indeed, our data showed increased
expression levels of genes involved in apoptosis signaling,
such as TNFSF10 (TRAIL), B-cell chronic lymphocytic
leukemia/lymphoma 10 (BCL10), STAT5B, GULP1
(CED6), and STK17B (DRAK2; Table E1 and Figure 2).
Cyanosis reduces transcription, MAPK signaling, and
contractile machinery. One of the dominant functional
classes for the downregulated genes was transcription.
The transcription factors that showed a reduction of expres-
sion levels included JUN, JUND, ATF2, STAT3, GATA4,
EPAS1, NCOA2, ARNT, and SP1 (Table E2 and
Figure 3, A).
Reduction of MAPK signaling genes emerged as another
important functional theme for the downregulated genes.
This was evident by the decreased expression levels of
MAPK1 (ERK), MAPK14 (SAPK2), MAP3K2, MAP3K3,
MAP4K4, AKT2, TAOK1, SOS1, and SOS2 (Table E2
and Figure 3, B). In addition, our data exhibited a downre-
gulation in the contractile machinery (cytoskeleton and
cell-adhesion clusters). The downregulated transcripts in-
cluded troponin T type 2, myosin XVIIIB, ARP2 actin-
related protein 2 and nebulin-related anchoring protein
(Figure E1).ery c August 2010
FIGURE 3. Biological association networks of the significantly downregulated genes associated with the ontological ‘‘regulation of transcription’’ (A) and
‘‘MAPK signaling pathway’’ (B) classes. Each node in network maps is linked to an html page showing the protein annotation based on available public da-
tabases. Small square boxes connecting 2 nodes are linked to an html page showing the type of effect (positive or negative) and the supportingMedline references.
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DValidation of Differential Expression of Selected
Gene Products
Despite being greatly informative, changes in mRNA
levels are insufficient to predict protein expression levels.
We therefore went onto assessing the protein levels of the
identified genes in the myocardium and blood of cyanotic
and acyanotic children using immunohistochemistry, West-
ern blotting, and ELISA. By using immunohistochemistry,
we showed COX11, NCX1, OPN, TRAIL, and LYZ protein
immunostaining in the myocardium of cyanotic and acya-
notic children (Figures E2, C and D; E3, A and B, E4, C
and D; and E5, A and B). The strongest signals observed
were those of COX11 and LYZ. Subsequently, we semi-
quantitatively assessed protein level changes in the myocar-
dium of cyanotic and acyanotic children by using Western
blotting. COX11, OPN, and LYZ showed significant in-
creases in cyanotic samples compared with levels seen in
acyanotic samples (Figures E2, E and F; E5, C and D; and
E6, C and D), which is similar to that observed at the
mRNA level. NCX1 protein levels showed a significant
decrease caused by cyanosis (Figure E3, C and D), resem-
bling that obtained at the transcriptomic level. In contrast,
TRAIL protein levels showed no alteration in the myocar-
dium of the 2 groups of patients (Figure E4, A and B). Be-
cause TRAIL is a soluble protein that could be released in
blood, we assessed TRAIL plasma levels by means of
ELISA. Our data indicated a significant 42% increase of
TRAIL plasma levels in cyanotic compared with acyanotic
children (Figure E4, E).
Functional Validation
To functionally validate our transcriptomics-derived hy-
pothesis, we examined protein expression levels of markers
of hypoxia, apoptosis, and MAPK signaling activation in
myocardial tissue. Western blotting of hypoxia-inducible
factor 1 alpha showed a significant upregulation in cya-
notic compared with acyanotic tissue, confirming the hyp-
oxic state this patient group’s experiences (Figure E7, A).
Additionally, we showed a significant increase in cleaved
caspase-3 (activated form) and Bcl-2-associated X protein
(BAX) protein expression in cyanotic compared with acya-
notic myocardium (Figure E7, B and C). Caspase-3 is a crit-
ical apoptosis executioner, and BAX is a well-documented
apoptotic activator. Increased levels of cleaved caspase-3
and BAX in cyanotic myocardium indicate an increased
apoptotic activity in the hearts of these patients. Further-
more, we showed a significant decrease in phospho-
SAPK (activated form) expression levels in cyanotic com-
pared with acyanotic myocardium (Figure E7, D). We also
detected a tendency toward a decrease in phosphorylated
extracellular signal-regulated kinase (ERK) levels in cya-
notic myocardium, although it was not significant (data
not shown).342 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
The results of this microarray-based gene expression pro-
filing study seem toconfirm the existence of a reprogramming
response that is most evident in the chronically hypoxic cya-
noticmyocardium.Growth/morphogenesis, remodeling, and
apoptosis emerged as dominant functional themes for the up-
regulated genes (Figures 1 and 2). In contrast, transcription,
MAPK signaling, and contractile machinery (cytoskeleton
and adhesion) were the dominant functional classes for the
downregulated genes (Figures 1 and 3).
Previous studies have shown RVH in patients with TOF
compared with that seen in healthy control subjects.7,10
These studies did not differentiate between cyanotic and
acyanotic TOF. Our clinical data did not indicate a higher
RVH in cyanotic patients, suggesting that the observed
transcriptomic changes are mainly related to cyanosis. In our
investigation the expression level changes of extracellular
matrix factors (remodeling markers) in cyanotic compared
with acyanotic patients went in both directions. Indeed,
levels of FBLN1 and SPP1, for example, increased in
cyanotic patients, whereas levels of COL3A1, COL4A1,
COL4A2, COL6A1, COLA6A2, and COL12A1 decreased
(Figure E8). Increased levels of collagen I and III have been
shown to be associated with RV remodeling.10 It is tempting
to speculate that the right ventricle remodels differently in cy-
anotic and acyanotic patients, withmore injury-related reprog-
ramming occurring in cyanotic patients. However, in the
absence of gene expression data from age-matched healthy
control subjects, we are unable to validate such a hypothesis.
Our data showed increased gene expression levels of the
growth-signaling factors FGF7, TGFBR2, EGFR, and
insulin-like growth factor binding protein 7 (Table E1 and
Figure 2). These gene expression changes could be attributed
to a myocardial survival program in an attempt at protecting
itself from hypoxia-related cell damage. It is documented
that growth factors mediate the survival response in many
cell types,14 and the activation of growth factor signaling is
cardioprotective.15 A previous study showed an increased
expression level of VEGF in the right ventricle when com-
paring patients with TOF with healthy control subjects.10
Our findings showed no changes in VEGF expression levels
in cyanotic compared with acyanotic patients.
Additionally, our data showed increased apoptosis in cy-
anotic myocardium and increased expression of apoptosis
signaling genes, such as TNFSF10 (TRAIL), B-cell chronic
lymphocytic leukemia/lymphoma 10 (BCL10), STAT5B,
GULP1 (CED6), and STK17B (DRAK2; (Table E1 and
Figure 2). The protein encoded by BCL10 (CARMEN) con-
tains a caspase recruitment domain and has been shown to
induce apoptosis and to activate nuclear factor kB.16 The
protein encoded by STAT5B, a member of the signal trans-
ducer and activator of transcription family of transcription
factors, has been shown to be involved in diverse biologicalery c August 2010
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arily conserved adaptor protein required for efficient engulf-
ment of apoptotic cells by phagocytes.18 DRAK2 is
a member of the death-associated protein kinase family ca-
pable of inducing apoptosis on overexpression in cell cul-
ture.19 The activation of apoptosis signaling illustrates
how the chronic hypoxic stress seems to promote an injury
program within cyanotic patients’ myocardium. This pro-
gram might explain the worst reoxygenation injury that
cyanotic patients experience during and after corrective
heart surgery.4
Transcription,MAPK signaling, and contractilemachinery
(cytoskeleton and adhesion) were the important functional
classes for the downregulated genes (Figures 1 and 3).
Three of the identified downregulated transcription factors,
JUND, JUN, and ATF2, are players in both transcription
and MAPK signaling direct association networks (Figure 3).
Other downregulated transcription factors included
STA3, GATA4, EPAS1, ARNT, NCOA2, and SP1. The
reduction of transcription represents part of the injury-
related program initiated by chronic hypoxia. Indeed, fully
functional transcription machinery is crucial for myocardial
function and survival, and a decrease in transcription factor
levels would have a repercussion on cardiac function and
survival.
Similarly, the reduction of MAPK signaling is another
component of the injury-related program triggered by
chronic hypoxia. Indeed, the MAPK pathway is crucial for
myocyte survival and function. Decreased expression levels
of key players of this pathway (eg, activated SAPK) could
have a serious effect on the myocardium. Examples of the
MAPK pathway players that showed decreased expression
levels are MAPK1 (ERK), MAPK14 (SAPK2), MAP3K2,
MAP3K3, MAP4K4, AKT2, TAOK1, SOS1, and SOS2
(Table E2 and Figure 3, B). MAPKs phosphorylate a number
of known transcription factors to alter their transactivating
activities, thus presumably influencing gene expression to
elicit the cellular response.20 In cardiac myocytes members
of the ERK MAPK family have been implicated in survival
signaling in response to ischemia and reperfusion, oxidative
stress, and hypoxia.21 Other studies have also shown that the
MAPK/ERK kinase and phosphoinositide 3-kinase–protein
kinase Akt/protein kinase B pathways might protect against
apoptosis.14
In addition, our study showed a downregulation in the
contractile machinery (cytoskeleton and cell adhesion clus-
ters). The downregulated transcripts belonging to this group-
ing included troponin T type 2, myosin XVIIIB, ARP2
actin-related protein 2, and nebulin-related anchoring pro-
tein. The reduction of contractile machinery factors seems
to represent another part of the injury-related program initi-
ated by cyanosis. Such alteration of contractility factor levels
could explain the susceptibility of cyanotic patients to reox-
ygenation injury (Figure E1).The Journal of Thoracic and CaCOX11
Cytochrome-c oxidase 11 (COX11) showed important
upregulation in cyanotic patients at the mRNA and protein
levels. The COX11 protein is a constituent of the inner
mitochondrial membrane and might be involved in biosyn-
thesis of heme A. The upregulation of COX11 in our study
suggests that the cyanosis state might trigger a compensation
mechanism through COX11 and copper transport to palliate
the lack of oxygen.NCX1
The sodium-calcium (Naþ-Ca2þ) exchanger (NCX1,
SLC8A1) showed an important downregulation in cyanotic
patients at both the mRNA and protein levels. NCX1 is
a membrane protein that is considered to play an important
role in the Ca2þhandling of cardiac myocytes. The observed
NCX1 downregulation could decrease myocyte calcium
handling capacity, leading to mechanical dysfunction.TRAIL
TNFSF10 (TRAIL) showed also important upregulation
in cyanotic patients. TRAIL is a cytokine that belongs to
the tumor necrosis factor ligand family. The binding of
this protein to its receptors has been shown to trigger the ac-
tivation of MAPK8/c-Jun NH2-terminal kinase, caspase-8,
and caspase-3, thus inducing apoptosis.22 The observed
TRAIL increase in the circulation of cyanotic patients could
emanate from the myocardium. TRAIL increases in the cir-
culation of cyanotic patients could induce apoptosis in or-
gans and tissues expressing TRAIL receptors. The activity
of this protein might be modulated by binding to decoy re-
ceptors that cannot induce apoptosis. These decoy receptors,
such as osteoprotegerin, present great potential for use as
a therapy to reduce any TRAIL induced-apoptosis.SPP1
SPP1, also known as osteopontin (OPN), was upregulated
by 2-fold in cyanotic patients at the mRNA and protein
levels. OPN is expressed in the heart at low levels under nor-
mal conditions.23 Although the exact role of OPN in cardio-
myocyte function is unknown, there is evidence that
cardiomyocytes are a prominent source of OPN in vivo
and that induction of OPN expression is strongly associated
with ventricular remodeling.24 Additionally, increase of
OPN expression in the myocardium coincides with the de-
velopment of heart failure.25 Our data showed an increase
in OPN expression at the mRNA and protein levels in cya-
notic children, suggesting a remodeling program initiated
by chronic hypoxia in the myocardium.LYZ
LYZ (lysozyme) showed the highest upregulation (5:1) in
cyanotic patients. LYZ, the natural substrate of which isrdiovascular Surgery c Volume 140, Number 2 343
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agents found in human milk and is also present in the spleen,
lung, kidney, white blood cells, plasma, saliva, and tears.
Here we show protein expression of the LYZ gene product
in the ventricular myocardium and increased levels in cya-
notic compared with acyanotic patients. The biological sig-
nificance of this increase is not known, and further studies
would be required to uncover it.Limitations
Even though there was no difference between the 2 groups
in terms of right ventricular wall thickness, one cannot com-
pletely exclude the possibility that RVH could be a potential
confounder in our findings.
As expected, there was a difference in the 2 groups regard-
ing the preoperative use of b-blockers, and this might be
a potential confounding factor because it might influence
the course of RVH and remodeling.
We did not study normal or nondiseased right ventricular
myocardium; however, our focus was on the gene expres-
sion differences between cyanotic and acyanotic patients
with TOF.
Finally, our investigation can be interpreted as a descrip-
tive study that generates more hypotheses. However, it is our
belief that this will provide a better understanding of the
mechanisms associated with chronic hypoxia and help de-
velop interventions aimed at improving the clinical outcome
in this high-risk group of patients.
CONCLUSIONS
Overall, the transcriptional profile in the cyanotic group
was characterized by increased expression level of genes
with literature-validated apoptosis and growth/morphogene-
sis/remodeling properties. Furthermore, it showed decreased
expression levels of genes with cardiac function, cell sur-
vival, and cytoprotective properties. The molecular signa-
tures identified suggest a reprogramming response in the
cyanotic myocardium activated by the chronic hypoxia im-
posed by the structural congenital heart disease.
CLINICAL IMPLICATIONS
In this study patients in both groups (cyanotic and
acyanotic TOF) exhibited a significant hypertrophy of the
right ventricle caused by pressure overload. In cyanotic pa-
tients the higher degree of right ventricular obstruction and
the smaller size of the pulmonary annulus and main pulmo-
nary artery were responsible for the preoperative chronic
hypoxic state. We therefore believe that these 2 groups of
patients constitute the best possible model to study the influ-
ence of cyanosis on gene expression. Our analysis identified
several genes deregulated in the cyanotic heart that might be
responsible for the susceptibility of cyanotic children to
ischemia and reoxygenation injury during and after surgical344 The Journal of Thoracic and Cardiovascular Surgintervention. Indeed, our previous data4,5 showed that
cyanotic patients have significant perioperative myocardial
cell damage compared with acyanotic patients undergoing
cardiac surgery. This susceptibility to ischemia and
reperfusion damage can be explained by the impairment of
factors crucial to cardiac function, induction of apoptotic
pathways, and alteration of signal transduction pathways
seen in cyanotic patients in this study. This information
might have a significant effect in improving surgical
strategies in cyanotic patients with TOF undergoing
corrective cardiac surgery.
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FIGUREE1. Heat Map illustrating the expression levels of contractile machinery genes. A, Cytoskeletal cluster. B, Cell adhesion cluster. Hierarchical clus-
tering has been performed with ArrayStar software. A 3-color scale was used to illustrate expression level differences, with blue indicating low expression
values, yellow indicating intermediately expressed genes, and red representing highly expressed genes.
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FIGURE E2. COX 11 protein immunostaining of paraffin-embedded heart tissue from acyanotic (C) and cyanotic (D) patients using COX11-specific an-
tibody. 3,30-Diaminobenzidine (DAB) staining (brown) reveals expression of COX11 in both tissues but not in control tissue (A and B). E and F, COX11
protein expression level in myocardium of acyanotic (AC) and cyanotic (CC) patients. Biopsy specimens were lysed to isolate protein content and Western
blotting analysis was performed, probing for COX11 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). COX11 was significantly upregulated in
cyanotic biopsy specimens compared with that seen in acyanotic specimens. COX11 bands were normalized to glyceraldehude-3-phosphate dehydrogenase
(GAPDH) levels. Data are presented as means  standard errors of the mean. *P< .05 (n ¼ 6).
Ghorbel et al Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 140, Number 2 345.e2
C
H
D
FIGURE E3. A and B, NCX1 protein immunostaining of paraffin-embedded heart tissue from acyanotic (A) and cyanotic (B) patients using NCX1-specific
antibody. 3,30-Diaminobenzidine (DAB) staining (brown) reveals expression of NCX1 in both tissues. C and D, NCX1 protein expression level in myocar-
dium of acyanotic (AC) and cyanotic (CC) patients. Biopsy specimens were lysed to isolate protein content, and Western blotting analysis was performed,
probing for NCX1 and glyceraldehude-3-phosphate dehydrogenase (GAPDH). NCX1 was significantly downregulated in cyanotic biopsy specimens com-
pared with acyanotic specimens. NCX1 bands were normalized to GAPDH levels. Data are presented as means  standard errors of the mean. *P< .05
(n ¼ 4).
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FIGURE E4. TRAIL protein immunostaining of paraffin-embedded heart tissue from acyanotic (A) and cyanotic (B) patients using TRAIL-specific anti-
body. 3,30-Diaminobenzidine (DAB) staining (brown) reveals expression of TRAIL in both tissues. C and D, TRAIL protein expression level in myocardium
of acyanotic (AC) and cyanotic (CC) patients. Biopsy specimens were lysed to isolate protein content, and Western blotting analysis was performed, probing
for TRAIL and glyceraldehude-3-phosphate dehydrogenase (GAPDH). TRAIL was not upregulated in cyanotic biopsy specimens compared with acyanotic
specimens. TRAIL bands were normalized to GAPDH levels. Data are presented as means standard errors of the mean (n¼ 6). E, Plasma levels of TRAIL in
cyanotic (CC) and acyanotic (AC) children. Solid bars represent median protein concentration in preoperative plasma samples (in picograms per milliliter). A
significantly enhanced TRAIL protein expression was observed in cyanotic samples. Data are presented as means  standard errors of the mean. *P< .05
(n ¼ 9–11).
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FIGURE E5. LYZ protein immunostaining of paraffin-embedded heart tissue from acyanotic (A) and cyanotic (B) patients using LYZ-specific antibody.
3,30-Diaminobenzidine (DAB) staining (brown) reveals expression of LYZ in both tissues. C andD, LYZ protein expression level in myocardium of acyanotic
(AC) and cyanotic (CC) patients. Biopsy specimens were lysed to isolate protein content, and Western blotting analysis was performed, probing for LYZ and
glyceraldehude-3-phosphate dehydrogenase (GAPDH). LYZ was significantly upregulated in cyanotic biopsy specimens compared with acyanotic speci-
mens. LYZ bands were normalized to GAPDH levels. Data are presented as means  standard errors of the mean. *P< .05 (n ¼ 6).
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FIGURE E6. OPN protein immunostaining of paraffin-embedded heart tissue from acyanotic (A) and cyanotic (B) patients using OPN-specific antibody.
3,30-Diaminobenzidine (DAB) staining (brown) reveals expression of OPN in both tissues. C and D, OPN protein expression level in myocardium of acya-
notic (AC) and cyanotic (CC) patients. Biopsy specimens were lysed to isolate protein content, andWestern blotting analysis was performed, probing for OPN
and glyceraldehude-3-phosphate dehydrogenase (GAPDH). OPN was significantly upregulated in cyanotic biopsy specimens compared with acyanotic spec-
imens. OPN bands were normalized to GAPDH levels. Data are presented as means  standard errors of the mean. *P< .05 (n ¼ 6).
Ghorbel et al Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 140, Number 2 345.e6
C
H
D
FIGUREE7. Functional validation of hypoxia-inducible factor 1 alpha, cleaved caspase-3, BAX, and phospho-SAPK protein levels in myocardium of acya-
notic (AC) and cyanotic (CC) patients. Biopsy specimens were lysed to isolate protein content, and Western blotting analysis was performed, probing for
HIF1a (A), cleaved caspase-3 (B), BAX (C), phospho-SAPK (D) and glyceraldehude-3-phosphate dehydrogenase (GAPDH). HIF1a, cleaved caspase-3,
and BAXwere significantly upregulated in cyanotic compared with acyanotic biopsy specimens. Phospho-SAPKwas significantly downregulated in cyanotic
compared with acyanotic biopsy specimens. HIF1a, cleaved caspase-3, BAX, and phospho-SAPK bands were normalized to GAPDH levels. Data are pre-
sented as means  standard errors of the mean. *P< .05 (n ¼ 6).
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FIGURE E8. Heat Map illustrating the expression levels of the genes im-
plicated in extracellular matrix.Gene symbols in brown represent transcripts
that were upregulated in cyanotic patients, whereas gene symbols in green
represent genes downregulated by means of cyanosis. Hierarchical cluster-
ing has been performed with ArrayStar software. A 3-color scale was used
to illustrate expression level differences, with blue indicating low expres-
sion values, yellow indicating intermediately expressed genes, and red rep-
resenting highly expressed genes.
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TABLE E1. Genes exhibiting 1.8-fold or greater expression change in ventricular biopsy specimens of cyanotic versus acyanotic children
(upregulated genes)
Gene title Symbol Fold P value Gene ID
Lysozyme LYZ 5.103 up .0112 4069
Protein phosphatase 1, catalytic subunit, beta isoform PPP1CB 3.849 up .00559 5500
Early growth response 1 EGR1 3.498 up .0213 1958
RAP2C, member of RAS oncogene family RAP2C 3.364 up .0063 57826
Thrombospondin 1 THBS1 3.285 up .0265 7057
Nipsnap homolog 3A NIPSNAP3A 3.055 up .0229 25934
Ubiquitin B UBB 3.008 up .00998 7314
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 5, 13 kd
NDUFA5 2.984 up .0187 4698
EF-hand calcium binding domain 2 EFCAB2 2.946 up .0214 84288
Lactamase, beta 2 LACTB2 2.815 up .0139 51110
Hypothetical protein DKFZp564O0523 DKFZP564O0523 2.769 up .0101 84060
Beta-1,3-N-acetylgalactosaminyltransferase 1 B3GALNT1 2.748 up .0355 8706
Actin-binding rho-activating protein ABRA 2.711 up .0112 137735
Eukaryotic translation initiation factor 4E EIF4E 2.706 up .0133 1977
KIAA0776 KIAA0776 2.694 up .0372 23376
CDNA FLJ32626 fis, clone SYNOV1000045 2.692 up .0448
CDNA clone IMAGE:4820809 2.685 up .0113
COBW domain containing 1 CBWD1 2.681 up .0212 150472
Zinc finger E-box binding homeobox 2 ZEB2 2.671 up .0129 9839
Proteasome maturation protein POMP 2.639 up .0107 51371
Integral membrane protein 2A ITM2A 2.631 up .016 9452
Succinate-CoA ligase, GDP-forming, beta subunit SUCLG2 2.629 up .0443 8801
Ubiquitin-specific peptidase 28 USP28 2.612 up .0124 57646
Lysophospholipase I LYPLA1 2.583 up .0109 10434
KIAA0372 KIAA0372 2.579 up .0139 9652
Epidermal growth factor receptor (v-erb-b oncogene) EGFR 2.553 up .0102 1956
Family with sequence similarity 76, member B FAM76B 2.552 up .0473 143684
FYVE, RhoGEF and PH domain containing 4 FGD4 2.543 up .0211 121512
Hypothetical protein FLJ13611 FLJ13611 2.534 up .011 80006
COX11 homolog, cytochrome c oxidase assembly protein COX11 2.530 up .00736 1353
Hypothetical LOC401397 LOC401397 2.484 up .0167 401397
Kelch-like 20 KLHL20 2.435 up .0142 27252
FCF1 small subunit (SSU) processome component homolog FCF1 2.431 up .0163 93487
Calmodulin 3 (phosphorylase kinase, delta) CALM3 2.431 up .0205 808
Family with sequence similarity 73, member A FAM73A 2.431 up .0228 374986
CDNA clone IMAGE:5299642 2.407 up .0432
Proteasome (prosome, macropain) 26S subunit, ATPase, 2 PSMC2 2.368 up .0135 5701
Tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 2.363 up .0456 8743
CDNA clone IMAGE:5267328 2.361 up .016
Fibroblast growth factor 7 FGF7 2.338 up .0381 2252
EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 2.311 up .0422 2202
Cytochrome P450, family 51, subfamily A, polypeptide 1 CYP51A1 2.276 up .0113 1595
Protein phosphatase 1B (formerly 2C), magnesium-dependent,
beta isoform
PPM1B 2.264 up .00902 5495
Lumican LUM 2.260 up .025 4060
Serpin peptidase inhibitor, clade B (ovalbumin), member 9 SERPINB9 2.260 up .0391 5272
Amyotrophic lateral sclerosis 2 (juvenile) ALS2 2.256 up .0112 57679
Rab geranylgeranyltransferase, beta subunit RABGGTB 2.255 up .00808 5876
Ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast) UBE2D1 2.243 up .0281 7321
Hypothetical protein LOC386597 LOC386597 2.233 up .0107 386597
Tubulin, epsilon 1 TUBE1 2.213 up .0182 51175
COMM domain containing 8 COMMD8 2.204 up .016 54951
Erythropoietin receptor EPOR 2.190 up .016 2057
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TABLE E1. Continued
Gene title Symbol Fold P value Gene ID
Adaptor-related protein complex 1, sigma 2 subunit AP1S2 2.186 up .0454 8905
Striatin, calmodulin binding protein 3 STRN3 2.186 up .0243 29966
Phosphatase and actin regulator 2 PHACTR2 2.181 up .0203 9749
Zinc-binding alcohol dehydrogenase, domain containing 1 ZADH1 2.162 up .0266 145482
Tetraspanin 12 TSPAN12 2.159 up .036 23554
Transcribed locus 2.157 up .0121
Ankyrin 1, erythrocytic ANK1 2.148 up .0298 286
Adenosine kinase ADK 2.143 up .0113 132
Chromosome 18 open reading frame 55 C18orf55 2.140 up .0169 29090
Solute carrier family 22, member 25 UST6 2.130 up .0242 387601
Glycine amidinotransferase (L-arginine:glycine
amidinotransferase)
GATM 2.130 up .0343 2628
Arginyltransferase 1 ATE1 2.130 up .0291 11101
Serum deprivation response
(phosphatidylserine-binding protein)
SDPR 2.128 up .0391 8436
Calponin 3, acidic CNN3 2.125 up .0407 1266
Hypothetical protein LOC285708 LOC285708 2.110 up .0154 285708
2.106 up .0368
Chromosome 10 open reading frame 110 C10orf110 2.102 up .0482 55853
Stomatin (EPB72)–like 1 STOML1 2.099 up .011 9399
Heterogeneous nuclear ribonucleoprotein H1 (H) HNRPH1 2.092 up .0254 3187
Solute carrier family 2 (facilitated glucose transporter),
member 13
SLC2A13 2.092 up .0237 114134
Pallidin homolog (mouse) PLDN 2.087 up .0138 26258
Trinucleotide repeat containing 6B TNRC6B 2.079 up .0357 23112
Ubiquitin-conjugating enzyme E2D 1
(UBC4/5 homolog, yeast)
UBE2D1 2.075 up .0342 7321
Nuclear factor of activated T cells, cytoplasmic,
calcineurin-dependent 2 interacting protein
NFATC2IP 2.075 up .0136 84901
Syntaxin-binding protein 3 STXBP3 2.073 up .0115 6814
Transcription elongation factor B (SIII), polypeptide 1
(15 kd, elongin C)
TCEB1 2.071 up .0243 6921
EF-hand domain family, member A2 EFHA2 2.064 up .0142 286097
Lyrm7 homolog (mouse) LYRM7 2.052 up .0481 90624
ARP3 actin-related protein 3 homolog (yeast) ACTR3 2.048 up .0298 10096
Short coiled-coil protein SCOC 2.047 up .0213 60592
Ribosomal protein L15///similar to ribosomal protein L15 RPL15 2.047 up .0212 728088
Hypothetical LOC441642 LOC441642 2.046 up .0159 441642
CDNA clone IMAGE:4794011 2.043 up .0237
Homo sapiens, clone IMAGE:4480721, mRNA 2.043 up .0448
Chromosome 8 open reading frame 4 C8orf4 2.042 up .0388 56892
Polymerase (RNA) II (DNA directed) polypeptide K, 7.0 kd POLR2K 2.042 up .0176 5440
PRO1268 protein PRO1268 2.040 up .0237 29006
Sarcolemma-associated protein SLMAP 2.038 up .0169 7871
Glyceraldehyde-3-phosphate dehydrogenase–like 19///similar
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
GAPDHL19///
LOC732268
2.036 up .0153 442262///
732268
Eukaryotic translation initiation factor 4E EIF4E 2.033 up .0264 1977
WD repeat and SOCS box–containing 2 WSB2 2.031 up .0371 55884
CDNA FLJ32691 fis, clone TESTI2000221 2.022 up .00678
COMM domain containing 10 COMMD10 2.020 up .0196 51397
Zinc finger protein, X-linked ZFX 2.014 up .0112 7543
Ribosomal protein L23a pseudogene 7 RPL23AP7 2.011 up .0106 118433
SH3 domain–binding glutamic acid–rich protein like SH3BGRL 2.004 up .0214 6451
p21 (CDKN1A)–activated kinase 2 PAK2 2.002 up .0114 5062
Copine IV CPNE4 2.000 up .0172 131034
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Gene title Symbol Fold P value Gene ID
NLR family, pyrin domain containing 1 NLRP1 1.999 up .0303 22861
X-prolyl aminopeptidase (aminopeptidase P) 3, putative XPNPEP3 1.998 up .0379 63929
Ribosomal protein L37a RPL37A 1.997 up .035 6168
Protein tyrosine phosphatase type IVA, member 1 PTP4A1 1.989 up .0175 7803
CDNA FLJ30565 fis, clone BRAWH2005008 1.988 up .0169
Basic leucine zipper nuclear factor 1 (JEM-1) BLZF1 1.987 up .0405 8548
Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) KPNA2 1.986 up .0242 3838
Transcribed locus 1.982 up .0437
Insulin-like growth factor binding protein 7 IGFBP7 1.981 up .0404 3490
Centrosomal protein 170 kd CEP170 1.977 up .0458 9859
B-cell chronic lymphocytic leukemia/lymphoma 10 BCL10 1.964 up .0237 8915
Poly(A) binding protein interacting protein 1 PAIP1 1.962 up .0347 10605
Mediterranean fever MEFV 1.957 up .0137 4210
Similar to 60S ribosomal protein L35 LOC643653 1.957 up .0222 643653
Annexin A7 ANXA7 1.955 up .012 310
Folliculin FLCN 1.952 up .0255 201163
Septin 7 SEPT7 1.948 up .0483 989
TM2 domain containing 1 TM2D1 1.945 up .0157 83941
CD8a molecule CD8A 1.942 up .0186 925
Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I,
early T-lymphocyte activation 1)
SPP1 1.941 up .0115 6696
Selenoprotein P, plasma, 1 SEPP1 1.937 up .0206 6414
Transmembrane protein 123 TMEM123 1.935 up .011 114908
CDNA clone IMAGE:5273964 1.935 up .0483
Src kinase–associated phosphoprotein 2 SKAP2 1.934 up .0406 8935
Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) CDKN2C 1.933 up .0125 1031
1.927 up .024
Transcribed locus 1.926 up .0221
Spermidine/spermine N1-acetyltransferase 1 SAT1 1.925 up .0162 6303
THAP domain containing 5 THAP5 1.924 up .0113 168451
Actin-like 6A ACTL6A 1.923 up .0182 86
SMT3 suppressor of mif two 3 homolog 1 (S cerevisiae) SUMO1 1.922 up .00972 7341
MAD2 mitotic arrest deficient–like 1 (yeast) MAD2L1 1.922 up .0114 4085
MANSC domain containing 1 MANSC1 1.921 up .0232 54682
Endothelial differentiation, sphingolipid
G protein–coupled receptor, 1
EDG1 1.915 up .0242 1901
Wingless-type MMTV integration site family, member 6 WNT6 1.914 up .0387 7475
Carboxypeptidase E CPE 1.914 up .0236 1363
Transcribed locus 1.909 up .0315
Interleukin 33 IL33 1.901 up .0456 90865
OMA1 homolog, zinc metallopeptidase (S cerevisiae) OMA1 1.899 up .0263 115209
Calreticulin CALR 1.898 up .0443 811
Clone 114 tumor rejection antigen 1.895 up .0405
Solute carrier family 12
(sodium/potassium/chloride transporters), member 2
SLC12A2 1.893 up .0158 6558
1.893 up .0217
EF-hand domain family, member A1 EFHA1 1.892 up .0243 221154
Ribosomal protein L38 RPL38 1.890 up .0253 6169
Homo sapiens, clone IMAGE:5440917, mRNA 1.889 up .0374
Yip1 domain family, member 4 YIPF4 1.887 up .0146 84272
Guanine nucleotide binding protein (G protein),
gamma 10///hypothetical protein LOC552891
GNG10///
LOC552891
1.884 up .0224 2790///
552891
Peroxisomal biogenesis factor 7 PEX7 1.881 up .0135 5191
Signal transducer and activator of transcription 5B STAT5B 1.881 up .0195 6777
30(20), 50-Bisphosphate nucleotidase 1 BPNT1 1.876 up .0281 10380
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Gene title Symbol Fold P value Gene ID
Inhibitor of DNA binding 2, dominant negative
helix-loop-helix protein///inhibitor of DNA binding
2B, dominant negative helix-loop-helix protein
ID2///ID2B 1.875 up .0448 3398///84099
Eukaryotic translation initiation factor 1A, X-linked EIF1AX 1.866 up .0317 1964
OTU domain containing 6B OTUD6B 1.865 up .0325 51633
RAB12, member RAS oncogene family RAB12 1.864 up .024 201475
Late cornified envelope 1E LCE1E 1.862 up .00469 353135
RNA binding motif (RNP1, RRM) protein 3 RBM3 1.862 up .0125 5935
Thiopurine S-methyltransferase TPMT 1.858 up .0232 7172
Mitochondrial ribosomal protein L50 MRPL50 1.856 up .0389 54534
Hydroxysteroid dehydrogenase like 2 HSDL2 1.853 up .0352 84263
CDNA clone IMAGE:4830861 1.849 up .0181
Methylenetetrahydrofolate dehydrogenase
(NADPþ dependent) 2–like
MTHFD2L 1.847 up .0293 441024
Jagged 1 (Alagille syndrome) JAG1 1.847 up .0319 182
1.847 up .0111
Myozenin 2 MYOZ2 1.843 up .032 51778
Family with sequence similarity 115, member A FAM115A 1.842 up .0368 9747
Cysteine and histidine–rich domain
(CHORD)–containing 1
CHORDC1 1.841 up .0109 26973
ATPase, Caþþ transporting, type 2C, member 1 ATP2C1 1.841 up .0435 27032
Copine IV CPNE4 1.841 up .0149 131034
NLR family, pyrin domain containing 1 NLRP1 1.834 up .0241 22861
Basic transcription factor 3 BTF3 1.834 up .0104 689
Golgi transport 1 homolog B (S cerevisiae) GOLT1B 1.833 up .0312 51026
Transcribed locus 1.832 up .0171
Hypothetical protein FLJ22222 FLJ22222 1.829 up .0115 79701
Dihydropyrimidine dehydrogenase DPYD 1.826 up .0395 1806
Chromosome 5 open reading frame 33 C5orf33 1.825 up .0109 133686
Epidermal growth factor receptor (erythroblastic
leukemia viral (v-erb-b) oncogene homolog, avian)
EGFR 1.824 up .0152 1956
Jerky homolog–like (mouse) JRKL 1.824 up .0387 8690
Sphingomyelin synthase 1 SGMS1 1.824 up .0109 259230
Zinc finger protein 654 ZNF654 1.823 up .0367 55279
Transcribed locus (serine/threonine kinase 17B)
(apoptosis-inducing)
STK17B 1.819 up .0236
Gap junction protein, beta 4, 30.3 kd GJB4 1.814 up .032 127534
Sp3 transcription factor SP3 1.813 up .0124 6670
Leucine-rich repeat containing 25 LRRC25 1.813 up .028 126364
Transmembrane and tetratricopeptide repeat containing 3 TMTC3 1.813 up .0209 160418
Nucleosome assembly protein 1–like 1 NAP1L1 1.812 up .0266 4673
Fibrinogen-like 2 FGL2 1.812 up .0191 10875
Zinc finger protein 552 ZNF552 1.808 up .0125 79818
Hypothetical gene supported by AK023501 FLJ13439 1.808 up .0206 399876
Full-length insert cDNA clone ZD82B02 1.807 up .0197
Mesenchymal stem cell protein DSC96 1.805 up .034
Apolipoprotein B mRNA editing enzyme, catalytic
polypeptide–like 3G
APOBEC3G 1.803 up .0176 60489
Eukaryotic translation initiation factor 1A,
X-linked///eukaryotic translation initiation
factor 1A pseudogene 1
EIF1AP1///EIF1AX 1.803 up .0298 1964///280661
GULP, engulfment adaptor PTB domain containing 1 GULP1 1.801 up .0437 51454
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TABLE E2. Genes exhibiting 1.8-fold or greater expression change in ventricular biopsy specimens of cyanotic versus acyanotic children
(downregulated genes)
Gene title Symbol Fold P value Gene ID
Oxoglutarate (alpha-ketoglutarate)
dehydrogenase (lipoamide)
OGDH 6.227 down .0218 4967
Nebulin-related anchoring protein NRAP 5.878 down .0154 4892
Plakophilin 2 PKP2 5.058 down .0124 5318
Mitofusin 2 MFN2 4.453 down .0216 9927
Glucosamine (N-acetyl)-6-sulfatase GNS 4.439 down .0136 2799
AHNAK nucleoprotein AHNAK 4.417 down .011 79026
Solute carrier family 8 (sodium/calcium
exchanger), member 1
SLC8A1 4.284 down .00929 6546
Coatomer protein complex, subunit alpha COPA 4.221 down .0222 1314
Cardiomyopathy-associated 5 CMYA5 4.185 down .0118 202333
Phosphodiesterase 4D–interacting protein (myomegalin) PDE4DIP 3.875 down .0114 9659
Nuclear mitotic apparatus protein 1 NUMA1 3.768 down .0116 4926
SET domain containing 5 SETD5 3.652 down .0124 55209
Forkhead box O3 FOXO3 3.606 down .0271 2309
Solute carrier family 39 (zinc transporter), member 14 SLC39A14 3.589 down .0199 23516
Plectin 1, intermediate filament binding protein 500 kd PLEC1 3.542 down .0228 5339
Zinc finger protein 36, C3H type–like 2 ZFP36L2 3.495 down .0347 678
Homeodomain interacting protein kinase 3 HIPK3 3.485 down .0121 10114
Chromosome 19 open reading frame 6 C19orf6 3.457 down .0113 91304
Filamin binding LIM protein 1 FBLIM1 3.429 down .0314 54751
Interleukin 6 signal transducer (gp130,
oncostatin M receptor)
IL6ST 3.397 down .0114 3572
YTH domain family, member 3 YTHDF3 3.396 down .0146 253943
DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 DDX42 3.385 down .0124 11325
AF4/FMR2 family, member 4 AFF4 3.372 down .0136 27125
DEAH (Asp-Glu-Ala-His) box polypeptide 9 DHX9 3.350 down .011 1660
WD repeat domain 68 WDR68 3.246 down .0131 10238
ATPase type 13A3 ATP13A3 3.204 down .00672 79572
Sec61 alpha 1 subunit (S cerevisiae) SEC61A1 3.183 down .0175 29927
Chaperone, ABC1 activity of bc1 complex homolog CABC1 3.182 down .0219 56997
Signal-induced proliferation-associated 1 like 2 SIPA1L2 3.164 down .0183 57568
Gelsolin (amyloidosis, Finnish type) GSN 3.155 down .0125 2934
A kinase (PRKA) anchor protein 6 AKAP6 3.123 down .00579 9472
Peroxisome proliferator–activated receptor alpha PPARA 3.107 down .03 5465
PDZ and LIM domain 5 PDLIM5 3.101 down .0125 10611
Tetratricopeptide repeat domain 3 TTC3 3.088 down .0109 7267
Sp1 transcription factor SP1 3.080 down .0146 6667
Trafficking protein, kinesin binding 1 TRAK1 3.074 down .0224 22906
Inositol polyphosphate-5-phosphatase, 40 kd INPP5A 3.072 down .0145 3632
Phosphodiesterase 3A, cGMP-inhibited PDE3A 3.069 down .00601 5139
Suppressor of Ty 16 homolog (S cerevisiae) SUPT16H 3.057 down .0187 11198
Nucleoporin 62 kd NUP62 3.054 down .0161 23636
Proteasome (prosome, macropain) activator subunit 4 PSME4 3.047 down .0113 23198
FYVE, RhoGEF and PH domain containing 4 FGD4 3.043 down .00671 121512
ELKS/RAB6-interacting/CAST family member 1 ERC1 3.033 down .0219 23085
PRP6 pre-mRNA processing factor 6 homolog PRPF6 3.029 down .0125 24148
Collagen, type VI, alpha 1 COL6A1 3.000 down .00664 1291
Myotubularin related protein 1 MTMR1 2.983 down .00996 8776
CDNA FLJ38472 fis, clone FEBRA2022148 2.981 down .0437
Transformation/transcription domain–associated protein TRRAP 2.973 down .0136 8295
Ubiquitination factor E4B (UFD2 homolog, yeast) UBE4B 2.970 down .0116 10277
Myeloid cell leukemia sequence 1 (BCL2-related) MCL1 2.967 down .0218 4170
ATPase, Caþþ transporting, plasma membrane 4 ATP2B4 2.957 down .0121 493
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Filamin A interacting protein 1 FILIP1 2.950 down .0066 27145
Ribosomal protein S23 RPS23 2.945 down .0156 6228
Carboxypeptidase D CPD 2.937 down .0137 1362
F-box and WD repeat domain containing 11 FBXW11 2.925 down .0112 23291
LAG1 homolog, ceramide synthase 6 LASS6 2.914 down .0366 253782
SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a, member 2
SMARCA2 2.905 down .0111 6595
Sorbin and SH3 domain containing 1 SORBS1 2.894 down .0176 10580
Guanine nucleotide binding protein (G protein), alpha 13 GNA13 2.865 down .0241 10672
SCY1-like 2 (S cerevisiae) SCYL2 2.852 down .0119 55681
Fas (TNFRSF6) associated factor 1 FAF1 2.819 down .0139 11124
Ezrin EZR 2.818 down .0295 7430
Zinc finger protein 672 ZNF672 2.814 down .0144 79894
GATA binding protein 4 GATA4 2.805 down .0212 2626
Phosphodiesterase 1C, calmodulin-dependent 70 kd PDE1C 2.803 down .0109 5137
Fibroblast growth factor receptor 1 FGFR1 2.800 down .0132 2260
Muscleblind-like 2 (Drosophila) MBNL2 2.780 down .0244 10150
Ubiquitin protein ligase E3 component n-recognin 1 UBR1 2.771 down .0253 197131
Sodium channel, voltage-gated, type VII, alpha SCN7A 2.769 down .0113 6332
Collagen, type VI, alpha 2 COL6A2 2.742 down .0112 1292
Myelin basic protein MBP 2.742 down .0103 4155
Eukaryotic translation initiation factor 4 gamma, 1 EIF4G1 2.740 down .0125 1981
Exportin 7 XPO7 2.736 down .0112 23039
Endothelial PAS domain protein 1 EPAS1 2.725 down .0232 2034
MutS homolog 6 (E coli) MSH6 2.724 down .0129 2956
Transforming growth factor, beta receptor II (70/80 kd) TGFBR2 2.715 down .0124 7048
Gamma-aminobutyric acid (GABA) A receptor, beta 1 GABRB1 2.710 down .0311 2560
Pleckstrin homology–like domain, family B, member 2 PHLDB2 2.706 down .0174 90102
Catenin (cadherin-associated protein), alpha 1, 102 kd CTNNA1 2.703 down .0228 1495
Carboxyl ester lipase (bile salt–stimulated lipase) CEL 2.700 down .0449 1056
Prune homolog PRUNE 2.678 down .0233 58497
BCL2-like 1 BCL2L1 2.674 down .0329 598
Solute carrier family 16, member 1 (monocarboxylic
acid transporter 1)
SLC16A1 2.672 down .0128 6566
CDNA FLJ38048 fis, clone CTONG2014264///CDNA
FLJ39067 fis, clone NT2RP7014910
2.668 down .0154
ADP-ribosylation factor guanine nucleotide-exchange factor 2 ARFGEF2 2.654 down .0168 10564
Chromosome 9 open reading frame 5 C9orf5 2.650 down .01 23731
Zinc finger, MYND domain containing 11 ZMYND11 2.635 down .011 10771
Ras homolog gene family, member B RHOB 2.634 down .0488 388
Kringle containing transmembrane protein 1 KREMEN1 2.620 down .0448 83999
F-box protein 38 FBXO38 2.617 down .0125 81545
Secretory carrier membrane protein 1 SCAMP1 2.616 down .011 9522
Putative homeodomain transcription factor 2 PHTF2 2.605 down .0178 57157
Spastic paraplegia 7 SPG7 2.598 down .0451 6687
Membrane protein, palmitoylated 5 (MAGUK p55
subfamily member 5)
MPP5 2.595 down .0103 64398
BCL2-associated transcription factor 1 BCLAF1 2.585 down .0138 9774
Nuclear receptor coactivator 2 NCOA2 2.580 down .0116 10499
Myomesin family, member 3 MYOM3 2.579 down .0346 127294
Forkhead box N3 FOXN3 2.573 down .0118 1112
Blood vessel epicardial substance BVES 2.570 down .0295 11149
Family with sequence similarity 62 (C2 domain containing)
member B
FAM62B 2.569 down .0134 57488
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Gene title Symbol Fold P value Gene ID
Procollagen-proline, 2-oxoglutarate 4-dioxygenase
(proline 4-hydroxylase), beta polypeptide
P4HB 2.564 down .0384 5034
Ubiquitin-specific peptidase 2 USP2 2.544 down .00576 9099
Zinc finger, FYVE domain containing 1 ZFYVE1 2.540 down .0149 53349
General transcription factor II, i GTF2I 2.539 down .0135 2969
Son of sevenless homolog 2 SOS2 2.539 down .0211 6655
Thrombospondin, type I, domain containing 4 THSD4 2.536 down .0177 79875
Jumonji domain containing 1C JMJD1C 2.533 down .0098 221037
Ring finger protein 38 RNF38 2.532 down .00664 152006
Muscleblind-like MBNL1 2.517 down .0418 4154
Coiled-coil domain containing 93 CCDC93 2.515 down .0102 54520
Cleft lip and palate associated transmembrane protein 1 CLPTM1 2.505 down .0301 1209
HECT domain containing 1 HECTD1 2.502 down .0133 25831
Transmembrane protein 168 TMEM168 2.500 down .00924 64418
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 2.495 down .0306 6480
Glutamate-ammonia ligase (glutamine synthetase) GLUL 2.493 down .0239 2752
WD repeat domain 1 WDR1 2.490 down .0212 9948
UBX domain containing 7 UBXD7 2.483 down .0233 26043
Dihydrolipoamide branched chain transacylase E2 DBT 2.482 down .0161 1629
Zinc finger, BED-type containing 1 ZBED1 2.478 down .0168 9189
Solute carrier family 29 (nucleoside transporters), member 1 SLC29A1 2.476 down .0163 2030
Mitogen-activated protein kinase 14 MAPK14 2.472 down .0205 1432
GRB2-associated binding protein 1 GAB1 2.465 down .00951 2549
Coiled-coil domain containing 22 CCDC22 2.461 down .0137 28952
Latent transforming growth factor beta binding protein 3 LTBP3 2.459 down .0169 4054
Replication initiator 1 REPIN1 2.455 down .0256 29803
Utrophin UTRN 2.452 down .0111 7402
Signal recognition particle receptor ("docking protein") SRPR 2.451 down .0181 6734
Forkhead box J3 FOXJ3 2.450 down .0142 22887
Collagen, type XII, alpha 1 COL12A1 2.446 down .0109 1303
TIMP metallopeptidase inhibitor 3 (Sorsby fundus
dystrophy, pseudoinflammatory)
TIMP3 2.445 down .0338 7078
Sperm associated antigen 9 SPAG9 2.445 down .0109 9043
Zinc finger protein 395 ZNF395 2.441 down .0264 55893
A kinase (PRKA) anchor protein 1 AKAP1 2.437 down .0226 8165
Activating transcription factor 2 ATF2 2.434 down .0145 1386
Collagen, type IV, alpha 2 COL4A2 2.431 down .0277 1284
Myelin basic protein MBP 2.427 down .00494 4155
Golgi associated PDZ and coiled-coil motif containing GOPC 2.424 down .00952 57120
Microfibrillar-associated protein 3 MFAP3 2.423 down .0171 4238
UBX domain containing 2 UBXD2 2.420 down .0136 23190
Heparan sulfate proteoglycan 2 HSPG2 2.415 down .0109 3339
Desmoglein 2 DSG2 2.411 down .0203 1829
Exocyst complex component 4 EXOC4 2.410 down .019 60412
Chloride intracellular channel 4 CLIC4 2.410 down .0207 25932
RAN binding protein 2 RANBP2 2.405 down .0116 5903
Ring finger and CCCH-type zinc finger domains 2 RC3H2 2.405 down .0119 54542
ATP-binding cassette, sub-family C (CFTR/MRP),
member 9
ABCC9 2.402 down .0066 10060
LSM14B, SCD6 homolog B (S cerevisiae) LSM14B 2.396 down .0118 149986
Synaptopodin 2 SYNPO2 2.395 down .0246 171024
Tripeptidyl peptidase I TPP1 2.391 down .0215 1200
Sema domain, transmembrane domain (TM), and cytoplasmic
domain, (semaphorin) 6D
SEMA6D 2.386 down .0442 80031
Discs, large homolog 1 (Drosophila) DLG1 2.382 down .0197 1739
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Obscurin-like 1 OBSL1 2.381 down .0441 23363
Ubiquitination factor E4B (UFD2 homolog, yeast) UBE4B 2.377 down .0108 10277
LIM domain containing preferred translocation partner in lipoma LPP 2.372 down .0134 4026
Plakophilin 4 PKP4 2.366 down .00687 8502
Dual specificity phosphatase 3 (vaccinia virus phosphatase
VH1-related)
DUSP3 2.361 down .0233 1845
Phosphatase and actin regulator 2 PHACTR2 2.361 down .0158 9749
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked DDX3X 2.357 down .0208 1654
Protein tyrosine phosphatase, nonreceptor type 11 (Noonan
syndrome 1)
PTPN11 2.351 down .0112 5781
Chromosome 6 open reading frame 106 C6orf106 2.348 down .012 64771
Rho GTPase activating protein 5 ARHGAP5 2.348 down .0103 394
Runt-related transcription factor 1; translocated to, 1
(cyclin D-related)
RUNX1T1 2.348 down .0119 862
Phosphoinositide-3-kinase, class 2, alpha polypeptide PIK3C2A 2.347 down .0169 5286
Phospholipase D1, phosphatidylcholine-specific PLD1 2.347 down .0256 5337
Dystrophin (muscular dystrophy, Duchenne and Becker types) DMD 2.344 down .00618 1756
Ankyrin 2, neuronal ANK2 2.343 down .00798 287
Janus kinase 1 (a protein tyrosine kinase) JAK1 2.340 down .0227 3716
Lamin A/C LMNA 2.335 down .0134 4000
Bromodomain containing 4 BRD4 2.334 down .039 23476
Ubiquitin specific peptidase 42 USP42 2.321 down .0166 84132
Methyl CpG binding protein 2 (Rett syndrome) MECP2 2.320 down .0479 4204
Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase)
TGM2 2.319 down .0206 7052
Ankylosis, progressive homolog (mouse) ANKH 2.312 down .0205 56172
Muskelin 1, intracellular mediator containing kelch motifs MKLN1 2.311 down .0249 4289
Lysosomal-associated membrane protein 1 LAMP1 2.311 down .0274 3916
CUG triplet repeat, RNA binding protein 1 CUGBP1 2.309 down .0112 10658
Secretory carrier membrane protein 1 SCAMP1 2.308 down .0113 9522
WD repeat domain 68 WDR68 2.307 down .0172 10238
Ribosomal protein S6 kinase, 90 kd, polypeptide 2 RPS6KA2 2.304 down .0354 6196
Junctional adhesion molecule 3 JAM3 2.303 down .0158 83700
Bromodomain containing 2 BRD2 2.294 down .022 6046
Phosphatidylinositol 4-kinase, catalytic, beta PI4KB 2.292 down .0128 5298
Jun D proto-oncogene JUND 2.289 down .0242 3727
Microtubule associated serine/threonine kinase
family member 4
MAST4 2.285 down .0448 375449
Utrophin UTRN 2.284 down .011 7402
Chromosome 11 open reading frame 30 C11orf30 2.284 down .0433 56946
RAB6A, member RAS oncogene family RAB6A 2.283 down .0134 5870
Chromosome 4 open reading frame 18 C4orf18 2.283 down .0142 51313
Protein tyrosine phosphatase, non-receptor type 11
(Noonan syndrome 1)
PTPN11 2.283 down .00661 5781
Upstream binding transcription factor, RNA polymerase I UBTF 2.281 down .0101 7343
Collagen, type VI, alpha 1 COL6A1 2.280 down .0169 1291
Calcium channel, voltage-dependent, beta 2 subunit CACNB2 2.280 down .0449 783
Corin, serine peptidase CORIN 2.277 down .0284 10699
Spire homolog 1 (Drosophila) SPIRE1 2.276 down .0311 56907
Collagen, type VI, alpha 1 COL6A1 2.273 down .00933 1291
Angiopoietin-like 2 ANGPTL2 2.272 down .0125 23452
Sortilin 1 SORT1 2.271 down .0214 6272
Vacuolar protein sorting 35 homolog (S cerevisiae) VPS35 2.269 down .0219 55737
ADAM metallopeptidase domain 9 (meltrin gamma) ADAM9 2.269 down .016 8754
Palladin, cytoskeletal associated protein PALLD 2.266 down .0127 23022
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Tumor necrosis factor receptor superfamily, member 19 TNFRSF19 2.258 down .0218 55504
Zinc finger protein, X-linked///zinc finger protein, Y-linked ZFX///ZFY 2.256 down .0216 7543///7544
Oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) OGDH 2.251 down .0124 4967
CDV3 homolog (mouse) CDV3 2.251 down .0111 55573
Meningioma expressed antigen 5 (hyaluronidase) MGEA5 2.245 down .0113 10724
Solute carrier family 7 (cationic amino acid transporter,
yþsystem), member 6
SLC7A6 2.245 down .0455 9057
Component of oligomeric Golgi complex 3 COG3 2.241 down .0125 83548
Protein tyrosine phosphatase, non-receptor type 21 PTPN21 2.239 down .0199 11099
Obscurin-like 1 OBSL1 2.238 down .0324 23363
Phosphorylase kinase, gamma 1 (muscle) PHKG1 2.236 down .0239 5260
LanC lantibiotic synthetase component C-like 1 (bacterial) LANCL1 2.234 down .0183 10314
Obscurin-like 1 OBSL1 2.229 down .0282 23363
Ubiquitin specific peptidase 47 USP47 2.227 down .00285 55031
Structural maintenance of chromosomes 3 SMC3 2.226 down .0134 9126
Ankyrin repeat and KH domain containing 1 ANKHD1 2.225 down .0259 404734
Kelch repeat and BTB (POZ) domain containing 2 KBTBD2 2.225 down .0116 25948
Arginine-glutamic acid dipeptide (RE) repeats RERE 2.224 down .0448 473
Nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 2 interacting protein
NFATC2IP 2.223 down .0151 84901
Spire homolog 1 (Drosophila) SPIRE1 2.217 down .0146 56907
Protein phosphatase 1, regulatory (inhibitor) subunit 3B PPP1R3B 2.217 down .0234 79660
Versican VCAN 2.212 down .0487 1462
Mitogen-activated protein kinase 14 MAPK14 2.210 down .0377 1432
ARP2 actin-related protein 2 homolog (yeast) ACTR2 2.205 down .0088 10097
Sorbin and SH3 domain containing 1 SORBS1 2.205 down .0112 10580
Son of sevenless homolog 2 (Drosophila) SOS2 2.204 down .0404 6655
Mitogen-activated protein kinase 14 MAPK14 2.201 down .0111 1432
Glucosaminyl (N-acetyl) transferase 2, I-branching
enzyme (I blood group)
GCNT2 2.194 down .0255 2651
MRNA; cDNA DKFZp451B209 (from clone
DKFZp451B209)
2.193 down .028
ARP2 actin-related protein 2 homolog (yeast) ACTR2 2.193 down .0167 10097
Syntaxin 16 STX16 2.192 down .0145 8675
Non-POU domain containing, octamer-binding NONO 2.190 down .0255 4841
Jumonji, AT rich interactive domain 1B JARID1B 2.189 down .0274 10765
Replication protein A1, 70 kd RPA1 2.185 down .0103 6117
Sorting nexin 13 SNX13 2.183 down .0124 23161
Neural cell adhesion molecule 1 NCAM1 2.177 down .0119 4684
Ubiquitin protein ligase E3B UBE3B 2.177 down .012 89910
Endoplasmic reticulum aminopeptidase 2 ERAP2 2.172 down .0346 64167
Mitogen-activated protein kinase kinase kinase kinase 5 MAP4K5 2.171 down .0111 11183
Chromosome 6 open reading frame 166 C6orf166 2.168 down .0171 55122
Prickle homolog 1 (Drosophila) PRICKLE1 2.168 down .0424 144165
Erythrocyte membrane protein band 4.1-like 2 EPB41L2 2.168 down .0116 2037
Platelet-activating factor acetylhydrolase, isoform Ib,
alpha subunit 45 kd
PAFAH1B1 2.165 down .0262 5048
Chromosome 1 open reading frame 55 C1orf55 2.164 down .0169 163859
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,
neuro/glioblastoma derived oncogene homolog (avian)
ERBB2 2.163 down .0132 2064
DnaJ (Hsp40) homolog, subfamily C, member 14 DNAJC14 2.163 down .0253 85406
Family with sequence similarity 115, member A///family
with sequence similarity 115, member B
FAM115A///
FAM115B
2.162 down .011 653199///9747
Trans-Golgi network protein 2 TGOLN2 2.160 down .0212 10618
Presenilin 1 (Alzheimer disease 3) PSEN1 2.160 down .0142 5663
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Cbp/p300-interacting transactivator, with Glu/Asp-rich
carboxy-terminal domain, 2
CITED2 2.160 down .0323 10370
Ubiquitin-like modifier activating enzyme 1 UBA1 2.159 down .0234 7317
Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha PIP5K1A 2.157 down .0366 8394
B-cell chronic lymphocytic leukemia/lymphoma 6 (zinc
finger protein 51)
BCL6 2.156 down .0463 604
Zinc finger protein 317 ZNF317 2.155 down .0206 57693
Sorting nexin 13 SNX13 2.153 down .0236 23161
SUMO1/sentrin/SMT3 specific peptidase 3 SENP3 2.150 down .0127 26168
Structural maintenance of chromosomes 3 SMC3 2.149 down .0115 9126
Methionine adenosyltransferase II, alpha MAT2A 2.148 down .0187 4144
Polymerase (DNA-directed), delta interacting protein 3 POLDIP3 2.145 down .0133 84271
Receptor interacting protein kinase 5 RIPK5 2.139 down .012 25778
Retinoic acid receptor, beta RARB 2.137 down .0307 5915
O-linked N-acetylglucosamine (GlcNAc) transferase
(UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl
transferase)
OGT 2.136 down .0154 8473
PTPRF interacting protein, binding protein 1 (liprin beta 1) PPFIBP1 2.136 down .012 8496
Trinucleotide repeat containing 6C TNRC6C 2.136 down .0124 57690
FRY-like FRYL 2.134 down .0128 285527
Ankyrin repeat and FYVE domain containing 1 ANKFY1 2.134 down .0125 51479
DIP2 disco-interacting protein 2 homolog C (Drosophila) DIP2C 2.134 down .0113 22982
ARP2 actin-related protein 2 homolog (yeast) ACTR2 2.133 down .015 10097
Deleted in liver cancer 1 DLC1 2.132 down .0206 10395
ets variant gene 1 ETV1 2.131 down .0239 2115
Translocated promoter region (to activated MET oncogene) TPR 2.131 down .0243 7175
Signal transducer and activator of transcription 3
(acute-phase response factor)
STAT3 2.130 down .0187 6774
Calcium binding protein 39 CAB39 2.129 down .0217 51719
Glutamine and serine rich 1 QSER1 2.129 down .0119 79832
Actin binding LIM protein 1 ABLIM1 2.127 down .017 3983
Zinc finger protein 36, C3H type-like 2 ZFP36L2 2.125 down .0394 678
Junctional adhesion molecule 3 JAM3 2.122 down .00921 83700
Golgi autoantigen, golgin subfamily a, 2 GOLGA2 2.121 down .0272 2801
Nuclear factor I/A NFIA 2.121 down .0102 4774
Cholinergic receptor, muscarinic 2 CHRM2 2.120 down .0355 1129
Ankyrin 3, node of Ranvier (ankyrin G) ANK3 2.120 down .0365 288
Neuroblastoma breakpoint family, member 1 NBPF1 2.117 down .0114 149013
FRY-like FRYL 2.115 down .0254 285527
UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 2 (GalNAc-T2)
GALNT2 2.113 down .0158 2590
MAP/microtubule affinity-regulating kinase 2 MARK2 2.113 down .0376 2011
Transmembrane 9 superfamily protein member 4 TM9SF4 2.113 down .0212 9777
Nucleobindin 1 NUCB1 2.109 down .0258 4924
Rho GTPase activating protein 26 ARHGAP26 2.109 down .0228 23092
Dynactin 1 (p150, glued homolog, Drosophila) DCTN1 2.109 down .0157 1639
Ubiquitin specific peptidase 10 USP10 2.106 down .0209 9100
Squamous cell carcinoma antigen recognized by T cells 3 SART3 2.105 down .0113 9733
Importin 8 IPO8 2.104 down .0137 10526
Hepatocyte growth factor-regulated tyrosine kinase substrate HGS 2.103 down .0206 9146
Solute carrier family 8 (sodium/calcium exchanger), member 1 SLC8A1 2.102 down .0122 6546
Protein tyrosine phosphatase, non-receptor type 12 PTPN12 2.102 down .041 5782
Chloride intracellular channel 4 CLIC4 2.100 down .026 25932
FK506 binding protein 15, 133 kd FKBP15 2.099 down .0249 23307
Insulin-like growth factor binding protein 5 IGFBP5 2.097 down .0263 3488
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ATPase, Hþ transporting, lysosomal 70 kd, V1
subunit A
ATP6V1A 2.097 down .0143 523
Neighbor of BRCA1 gene 1///similar to
neighbor of BRCA1 gene 1
LOC727732///
NBR1
2.096 down .0126 4077///727732
TEA domain family member 2 TEAD2 2.096 down .0399 8463
Cytokine-like nuclear factor n-pac N-PAC 2.095 down .0225 84656
CCR4-NOT transcription complex, subunit 1 CNOT1 2.093 down .0122 23019
Myosin XVIIIB MYO18B 2.090 down .0218 84700
Leucine-rich repeats and immunoglobulin-like domains 1 LRIG1 2.090 down .0134 26018
Zinc finger protein 514 ZNF514 2.090 down .0335 84874
Apolipoprotein E APOE 2.088 down .0284 348
Minichromosome maintenance complex component 7 MCM7 2.086 down .0258 4176
Arsenate resistance protein 2 ARS2 2.082 down .0209 51593
N-acetyltransferase 11 NAT11 2.081 down .0317 79829
GM2 ganglioside activator GM2A 2.079 down .0372 2760
Jun D proto-oncogene JUND 2.079 down .0218 3727
Mitogen-activated protein kinase kinase kinase 2 MAP3K2 2.077 down .00667 10746
Karyopherin alpha 1 (importin alpha 5) KPNA1 2.076 down .0169 3836
YY1 transcription factor YY1 2.075 down .048 7528
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum
protein retention receptor 1
KDELR1 2.074 down .0175 10945
Prolyl endopeptidase-like PREPL 2.072 down .0113 9581
O-linked N-acetylglucosamine (GlcNAc) transferase
(UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl
transferase)
OGT 2.072 down .0136 8473
Insulin-like growth factor 2 receptor IGF2R 2.072 down .0102 3482
Zinc finger protein 275 ZNF275 2.070 down .0462 10838
Zinc finger, MYM-type 2 ZMYM2 2.069 down .0255 7750
GTPase activating protein (SH3 domain) binding protein 2 G3BP2 2.069 down .0134 9908
CDNA FLJ33081 fis, clone TRACH2000321 2.069 down .0287
KIAA0430 KIAA0430 2.068 down .0136 9665
ets variant gene 1 ETV1 2.068 down .0125 2115
Leucine rich repeat (in FLII) interacting protein 2 LRRFIP2 2.067 down .0162 9209
Endothelial differentiation, lysophosphatidic acid
G-protein-coupled receptor, 7
EDG7 2.066 down .0437 23566
Obscurin-like 1 OBSL1 2.066 down .0243 23363
Retinoblastoma-like 2 (p130) RBL2 2.065 down .0175 5934
Ubiquitin-conjugating enzyme E2G 2 (UBC7
homolog, yeast)
UBE2G2 2.065 down .0125 7327
Calcium channel, voltage-dependent, alpha
2/delta subunit 1
CACNA2D1 2.062 down .0237 781
Uridine-cytidine kinase 1-like 1 UCKL1 2.062 down .0344 54963
Bromodomain containing 2 BRD2 2.059 down .0473 6046
Tripartite motif-containing 56 TRIM56 2.059 down .0129 81844
AF4/FMR2 family, member 4 AFF4 2.059 down .0442 27125
Ubiquitously transcribed tetratricopeptide repeat,
X chromosome
UTX 2.058 down .0299 7403
Spectrin, beta, nonerythrocytic 1 SPTBN1 2.057 down .017 6711
Striatin, calmodulin binding protein STRN 2.057 down .0113 6801
Uridine-cytidine kinase 1 UCK1 2.056 down .0281 83549
Solute carrier family 2 (facilitated glucose transporter),
member 11
SLC2A11 2.055 down .0197 66035
Hypothetical LOC552889 LOC552889 2.053 down .0136 552889
Peroxisome proliferator-activated receptor alpha PPARA 2.051 down .0151 5465
Chromosome 10 open reading frame 46 C10orf46 2.051 down .0163 143384
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Outer dense fiber of sperm tails 2 ODF2 2.049 down .0114 4957
O-linked N-acetylglucosamine (GlcNAc) transferase
(UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl
transferase)
OGT 2.048 down .016 8473
Janus kinase 1 (a protein tyrosine kinase) JAK1 2.047 down .0312 3716
Structure specific recognition protein 1 SSRP1 2.047 down .0211 6749
Glutamyl-prolyl-tRNA synthetase EPRS 2.047 down .0149 2058
Karyopherin alpha 4 (importin alpha 3) KPNA4 2.045 down .0126 3840
MAD1 mitotic arrest deficient-like 1 (yeast) MAD1L1 2.045 down .0331 8379
Zinc finger CCCH-type containing 11A ZC3H11A 2.045 down .0113 9877
Ubiquitin specific peptidase 25 USP25 2.044 down .0103 29761
Tribbles homolog 2 (Drosophila) TRIB2 2.044 down .00966 28951
Adenomatous polyposis coli APC 2.043 down .0111 324
Centrosomal protein 68 kd CEP68 2.040 down .0174 23177
Protein phosphatase 1, regulatory (inhibitor) subunit 12B PPP1R12B 2.040 down .012 4660
v-crk sarcoma virus CT10 oncogene homolog (avian) CRK 2.037 down .022 1398
Protein phosphatase 2, regulatory subunit B0, delta isoform PPP2R5D 2.034 down .0319 5528
GATA zinc finger domain containing 1 GATAD1 2.033 down .0295 57798
Dipeptidyl-peptidase 8 DPP8 2.031 down .0442 54878
Mitochondrial tumor suppressor 1 MTUS1 2.030 down .0258 57509
Ubiquitination factor E4B (UFD2 homolog, yeast) UBE4B 2.028 down .0118 10277
Fusion (involved in t(12;16) in malignant liposarcoma) FUS 2.027 down .0394 2521
Hippocalcin-like 1 HPCAL1 2.027 down .0449 3241
ATP-binding cassette, sub-family C (CFTR/MRP), member 9 ABCC9 2.027 down .0125 10060
Protein tyrosine phosphatase, non-receptor type 21 PTPN21 2.025 down .0234 11099
Ubiquitin specific peptidase 34 USP34 2.024 down .0159 9736
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked DDX3X 2.024 down .0203 1654
Phosphatidylinositol binding clathrin assembly protein PICALM 2.023 down .0158 8301
Transportin 3 TNPO3 2.022 down .0166 23534
Non-POU domain containing, octamer-binding NONO 2.022 down .0192 4841
ORM1-like 3 (S cerevisiae) ORMDL3 2.021 down .014 94103
Mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4 2.021 down .0371 9448
Tribbles homolog 1 (Drosophila) TRIB1 2.021 down .0206 10221
WD repeat domain 6 WDR6 2.020 down .0135 11180
Aspartate beta-hydroxylase ASPH 2.020 down .00586 444
Zinc finger protein 45 ZNF45 2.019 down .0125 7596
SET domain containing 5 SETD5 2.019 down .0266 55209
Eukaryotic translation initiation factor 4E nuclear import factor 1 EIF4ENIF1 2.017 down .0142 56478
High-density lipoprotein binding protein (vigilin) HDLBP 2.013 down .0162 3069
Mannosyl (alpha-1,3-)-glycoprotein beta-1,
4-N-acetylglucosaminyltransferase, isozyme B
MGAT4B 2.012 down .0175 11282
AT rich interactive domain 1A (SWI-like) ARID1A 2.012 down .0426 8289
Alkylglycerone phosphate synthase AGPS 2.011 down .00981 8540
MLCK protein MLCK 2.010 down .0158 91807
FYVE, RhoGEF and PH domain containing 6 FGD6 2.009 down .0163 55785
Cytoplasmic FMR1 interacting protein 2 CYFIP2 2.007 down .0392 26999
Acyl-CoA thioesterase 11 ACOT11 2.003 down .0417 26027
Ubiquitin specific peptidase 11 USP11 2.001 down .0306 8237
Zinc finger protein 395///F-box protein 16 FBXO16///
ZNF395
2.000 down .035 157574///
55893
Adrenergic, alpha-1A-, receptor ADRA1A 1.998 down .0404 148
M-phase phosphoprotein 9 MPHOSPH9 1.996 down .0239 10198
Nudix (nucleoside diphosphate linked moiety X)-type motif 21 NUDT21 1.995 down .0167 11051
Kruppel-like factor 3 (basic) KLF3 1.993 down .0169 51274
Synovial sarcoma translocation, chromosome 18 SS18 1.992 down .0185 6760
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Exocyst complex component 5 EXOC5 1.991 down .016 10640
Rabaptin, RAB GTPase binding effector protein 1 RABEP1 1.990 down .0482 9135
PRP4 pre-mRNA processing factor 4 homolog (yeast) PRPF4 1.990 down .0206 9128
CDNA FLJ10151 fis, clone HEMBA1003402 1.986 down .0136
CDNA clone IMAGE:5263531 1.986 down .0114
SH3-domain GRB2-like endophilin B2 SH3GLB2 1.985 down .0301 56904
Serologically defined colon cancer antigen 1 SDCCAG1 1.985 down .0111 9147
Zinc finger protein 398 ZNF398 1.981 down .0365 57541
Cytochrome b reductase 1 CYBRD1 1.980 down .0237 79901
Transformation/transcription domain-associated protein TRRAP 1.977 down .0235 8295
SON DNA binding protein SON 1.975 down .0125 6651
Nucleoporin 133 kd NUP133 1.975 down .0187 55746
Discoidin domain receptor family, member 2 DDR2 1.973 down .0112 4921
A kinase (PRKA) anchor protein 8-like AKAP8L 1.971 down .0291 26993
Lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) LSS 1.971 down .0347 4047
dpy-19-like 1 (C elegans) DPY19L1 1.968 down .0174 23333
Dystonin DST 1.967 down .00579 667
Splicing factor, arginine/serine-rich 8
(suppressor-of-white-apricot homolog, Drosophila)
SFRS8 1.967 down .0239 6433
NGFI-A binding protein 1 (EGR1 binding protein 1) NAB1 1.965 down .0132 4664
Exocyst complex component 7 EXOC7 1.963 down .0278 23265
Syntrophin, beta 2 (dystrophin-associated protein A1, 59 kd,
basic component 2)
SNTB2 1.962 down .0196 6645
SEC63 homolog (S cerevisiae) SEC63 1.961 down .0142 11231
SHC (Src homology 2 domain containing) transforming
protein 1
SHC1 1.960 down .0129 6464
Engulfment and cell motility 2 ELMO2 1.960 down .021 63916
Chromosome 1 open reading frame 25 C1orf25 1.959 down .0309 81627
Glutamate-ammonia ligase (glutamine synthetase) GLUL 1.958 down .0355 2752
MYST histone acetyltransferase (monocytic leukemia) 4 MYST4 1.957 down .0229 23522
FOS-like antigen 2 FOSL2 1.957 down .0326 2355
KIAA0692 KIAA0692 1.957 down .025 23141
Potassium channel tetramerization domain containing 20 KCTD20 1.955 down .028 222658
WD repeat domain 26 WDR26 1.955 down .0125 80232
Senataxin SETX 1.953 down .0121 23064
Trinucleotide repeat containing 6B TNRC6B 1.951 down .00655 23112
Transmembrane 9 superfamily member 1 TM9SF1 1.951 down .0301 10548
Family with sequence similarity 108, member B1 FAM108B1 1.948 down .0404 51104
Transmembrane protein 30A TMEM30A 1.948 down .0137 55754
CTD (carboxy-terminal domain, RNA polymerase II,
polypeptide A) small phosphatase like 2
CTDSPL2 1.948 down .0238 51496
Zinc finger protein 24 ZNF24 1.947 down .011 7572
HLA-B associated transcript 3 BAT3 1.947 down .0299 7917
Chromosome 21 open reading frame 33 C21orf33 1.946 down .0321 8209
Protein kinase C substrate 80K-H PRKCSH 1.945 down .0205 5589
Pleckstrin homology, Sec7 and coiled-coil domains 3 PSCD3 1.943 down .0134 9265
BCL2-antagonist of cell death BAD 1.941 down .0326 572
A kinase (PRKA) anchor protein 10 AKAP10 1.941 down .0355 11216
Sorbin and SH3 domain containing 3 SORBS3 1.939 down .0162 10174
v-akt murine thymoma viral oncogene homolog 2 AKT2 1.939 down .035 208
Myeloid/lymphoid or mixed-lineage leukemia
(trithorax homolog, Drosophila)
MLL 1.939 down .0264 4297
Integrin, alpha 7 ITGA7 1.938 down .0256 3679
Ankyrin repeat and KH domain containing
1///ANKHD1-EIF4EBP3
ANKHD1///
ANKHD1-
EIF4EBP3
1.938 down .0401 404734///
54882
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CCR4-NOT transcription complex, subunit 4 CNOT4 1.937 down .0261 4850
CDNA FLJ38461 fis, clone FEBRA2020977 1.935 down .0168
Membrane-associated ring finger (C3HC4) 6 7-Mar 1.935 down .00973 10299
Zinc finger protein 540 ZNF540 1.934 down .024 163255
Solute carrier family 30 (zinc transporter), member 5 SLC30A5 1.934 down .00814 64924
Ral guanine nucleotide dissociation stimulator RALGDS 1.934 down .0212 5900
Mitogen-activated protein kinase 1 MAPK1 1.933 down .0124 5594
Small G protein signaling modulator 3 SGSM3 1.932 down .0354 27352
Intracisternal A particle-promoted polypeptide IPP 1.932 down .0337 3652
Mediator complex subunit 23 MED23 1.931 down .0242 9439
Bone morphogenetic protein receptor, type II
(serine/threonine kinase)
BMPR2 1.929 down .0111 659
MOCO sulphurase C-terminal domain containing 2 MOSC2 1.928 down .00932 54996
Myeloid/lymphoid or mixed-lineage leukemia
(trithorax homolog, Drosophila)
MLL 1.927 down .0172 4297
Troponin T type 2 (cardiac) TNNT2 1.926 down .0352 7139
ATPase, Hþ transporting, lysosomal V0 subunit a1 ATP6V0A1 1.925 down .0372 535
RAD23 homolog A (S cerevisiae) RAD23A 1.924 down .0205 5886
Nuclear receptor coactivator 3 NCOA3 1.924 down .0496 8202
Myelin basic protein MBP 1.924 down .0167 4155
Solute carrier family 33 (acetyl-CoA transporter),
member 1
SLC33A1 1.923 down .0112 9197
T-box 5 TBX5 1.923 down .0203 6910
DEAH (Asp-Glu-Ala-His) box polypeptide 9 DHX9 1.923 down .0112 1660
Intraflagellar transport 122 homolog (Chlamydomonas) IFT122 1.922 down .0247 55764
Calnexin CANX 1.921 down .0103 821
Rab and DnaJ domain containing RBJ 1.921 down .03 51277
Hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl-
coenzyme A thiolase/enoyl-coenzyme A hydratase
(trifunctional protein), alpha subunit
HADHA 1.921 down .0375 3030
Dystonin DST 1.919 down .0112 667
Phosphoinositide-3-kinase, class 2, alpha polypeptide PIK3C2A 1.919 down .0216 5286
ADAM metallopeptidase domain 10 ADAM10 1.918 down .0433 102
Fibronectin type III domain containing 3A FNDC3A 1.918 down .00672 22862
Spire homolog 1 (Drosophila) SPIRE1 1.917 down .0109 56907
RAS and EF-hand domain containing RASEF 1.917 down .0401 158158
Phosphodiesterase 1C, calmodulin-dependent 70 kd PDE1C 1.916 down .0136 5137
Ring finger protein 19A RNF19A 1.916 down .0112 25897
alkB, alkylation repair homolog 5 (E coli) ALKBH5 1.916 down .0208 54890
zer-1 homolog (C elegans) ZER1 1.915 down .0125 10444
Obscurin, cytoskeletal calmodulin and titin-interacting
RhoGEF
OBSCN 1.914 down .0387 84033
Zinc finger with KRAB and SCAN domains 1 ZKSCAN1 1.914 down .0142 7586
Chloride intracellular channel 5 CLIC5 1.913 down .0391 53405
WW domain containing adaptor with coiled-coil WAC 1.913 down .00669 51322
Wolfram syndrome 1 (wolframin) WFS1 1.912 down .0492 7466
Son of sevenless homolog 1 (Drosophila) SOS1 1.911 down .0448 6654
Cytoskeleton associated protein 5 CKAP5 1.909 down .0109 9793
Cullin 4B CUL4B 1.909 down .0204 8450
Paired related homeobox 1 PRRX1 1.908 down .0262 5396
Minichromosome maintenance complex component 3
associated protein
MCM3AP 1.907 down .0424 8888
Sp1 transcription factor SP1 1.906 down .0327 6667
Nuclear transcription factor Y, gamma NFYC 1.904 down .0239 4802
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v-rel reticuloendotheliosis viral oncogene homolog A,
nuclear factor of kappa light polypeptide gene
enhancer in B-cells 3, p65 (avian)
RELA 1.904 down .0498 5970
Chromosome 5 open reading frame 22 C5orf22 1.903 down .0126 55322
MYST histone acetyltransferase (monocytic leukemia) 4 MYST4 1.903 down .0135 23522
Iroquois homeobox 5 IRX5 1.903 down .0313 10265
Epoxide hydrolase 1, microsomal (xenobiotic) EPHX1 1.903 down .0158 2052
Microtubule associated monoxygenase, calponin and
LIM domain containing 3///similar to Protein MICAL-3
LOC731210
///MICAL3
1.903 down .0487 57553///
731210
Putative homeodomain transcription factor 2 PHTF2 1.902 down .04 57157
Mitogen-activated protein kinase kinase kinase 3 MAP3K3 1.901 down .0458 4215
Zinc finger protein 227 ZNF227 1.900 down .0262 7770
Membrane associated guanylate kinase, WW
and PDZ domain containing 2
MAGI2 1.900 down .035 9863
Bicaudal D homolog 2 (Drosophila) BICD2 1.900 down .0232 23299
Adducin 1 (alpha) ADD1 1.900 down .0136 118
Plexin B1 PLXNB1 1.900 down .034 5364
Adenylate cyclase 9 ADCY9 1.899 down .0163 115
Zinc finger CCCH-type containing 7A ZC3H7A 1.899 down .0118 29066
TOX high mobility group box family member
4///similar to Epidermal Langerhans cell protein LCP1
LOC285412
///TOX4
1.899 down .0263 285412///
9878
Nucleoporin 98 kd NUP98 1.898 down .0212 4928
Platelet derived growth factor C PDGFC 1.897 down .0461 56034
Block of proliferation 1///similar to block of proliferation 1 BOP1///
LOC727967
1.897 down .0448 23246///
727967
Obscurin, cytoskeletal calmodulin and titin-interacting
RhoGEF
OBSCN 1.896 down .0392 84033
guanine nucleotide binding protein (G protein), beta 5 GNB5 1.894 down .0396 10681
Protein tyrosine phosphatase, nonreceptor type 21 PTPN21 1.894 down .0278 11099
Adaptor-related protein complex 3, delta 1 subunit AP3D1 1.890 down .0112 8943
v-akt murine thymoma viral oncogene homolog 2 AKT2 1.889 down .0174 208
Solute carrier family 25 (mitochondrial carrier; adenine
nucleotide translocator), member 6
SLC25A6 1.889 down .0291 293
Zinc finger, DHHC-type containing 5 ZDHHC5 1.888 down .0136 25921
Latent transforming growth factor beta binding protein 1 LTBP1 1.888 down .0126 4052
Rho GTPase activating protein 26 ARHGAP26 1.887 down .0245 23092
ATPase, class I, type 8B, member 2 ATP8B2 1.885 down .0109 57198
Tuberous sclerosis 2 TSC2 1.885 down .0281 7249
ATPase, class VI, type 11A ATP11A 1.884 down .0107 23250
RIO kinase 3 (yeast) RIOK3 1.883 down .0238 8780
Golgi apparatus protein 1 GLG1 1.882 down .0234 2734
Nicotinamide nucleotide transhydrogenase NNT 1.880 down .0106 23530
Chromosome 19 open reading frame 6 C19orf6 1.879 down .0125 91304
Bromodomain containing 2 BRD2 1.879 down .0228 6046
Purine-rich element binding protein B PURB 1.879 down .0281 5814
Glutathione reductase GSR 1.879 down .00928 2936
ADP-ribosylation factor guanine nucleotide-exchange factor 1
(brefeldin A-inhibited)
ARFGEF1 1.877 down .00671 10565
ADP-ribosylation factor interacting protein 1 (arfaptin 1) ARFIP1 1.877 down .0116 27236
Rhotekin RTKN 1.876 down .0109 6242
Jumonji domain containing 3, histone lysine demethylase JMJD3 1.875 down .0102 23135
Zinc finger and SCAN domain containing 18 ZSCAN18 1.874 down .0223 65982
Kelch repeat and BTB (POZ) domain containing 4 KBTBD4 1.873 down .044 55709
PRP6 pre-mRNA processing factor 6 homolog (S cerevisiae) PRPF6 1.872 down .0132 24148
CCR4-NOT transcription complex, subunit 3 CNOT3 1.871 down .0226 4849
Congenital Heart Disease Ghorbel et al
345.e23 The Journal of Thoracic and Cardiovascular Surgery c August 2010
C
H
D
TABLE E2. Continued
Gene title Symbol Fold P value Gene ID
Zinc finger, RAN-binding domain containing 1 ZRANB1 1.870 down .0289 54764
Glucosidase, alpha; neutral AB GANAB 1.870 down .0149 23193
Protein tyrosine phosphatase, receptor type,
f polypeptide (PTPRF),
interacting protein (liprin), alpha 1
PPFIA1 1.870 down .0281 8500
Vitamin K epoxide reductase complex, subunit 1-like 1 VKORC1L1 1.869 down .0114 154807
Ring finger and CCCH-type zinc finger domains 2 RC3H2 1.869 down .0112 54542
F-box and leucine-rich repeat protein 15 FBXL15 1.869 down .0287 79176
Zinc finger, FYVE domain containing 9 ZFYVE9 1.869 down .0129 9372
Transcribed locus 1.867 down .0217
Trinucleotide repeat containing 6B TNRC6B 1.867 down .0128 23112
Anterior pharynx defective 1 homolog A (C elegans) APH1A 1.867 down .0317 51107
Protein phosphatase 5, catalytic subunit PPP5C 1.866 down .0448 5536
Zinc finger protein 289, ID1 regulated ZNF289 1.866 down .0462 84364
UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 2 (GalNAc-T2)
GALNT2 1.865 down .0191 2590
Solute carrier family 25, member 30 SLC25A30 1.864 down .0372 253512
Kelch-like 23 (Drosophila) KLHL23 1.864 down .0281 151230
RAB3 GTPase activating protein subunit 2
(non-catalytic)
RAB3GAP2 1.862 down .0129 25782
Ring finger and CCCH-type zinc finger domains 2 RC3H2 1.861 down .0128 54542
Phospholipase C, beta 4 PLCB4 1.859 down .016 5332
Glucosidase, beta (bile acid) 2 GBA2 1.858 down .0134 57704
Cyclin-dependent kinase inhibitor 1C (p57, Kip2) CDKN1C 1.858 down .0266 1028
WWC family member 3 WWC3 1.857 down .0109 55841
Tripeptidyl peptidase I TPP1 1.856 down .0294 1200
CD99 molecule-like 2 CD99L2 1.855 down .0203 83692
Zinc finger protein 655 ZNF655 1.853 down .0226 79027
Actin filament associated protein 1-like 1 AFAP1L1 1.853 down .016 134265
Eukaryotic translation initiation factor 4B EIF4B 1.852 down .0112 1975
p21 (CDKN1A)-activated kinase 2 PAK2 1.852 down .0125 5062
Poliovirus receptor PVR 1.852 down .00712 5817
RAB3 GTPase activating protein subunit 1 (catalytic) RAB3GAP1 1.852 down .0274 22930
Interleukin enhancer binding factor 3, 90 kd ILF3 1.851 down .0116 3609
Chromosome 6 open reading frame 106 C6orf106 1.850 down .03 64771
Purine-rich element binding protein A PURA 1.850 down .0384 5813
Wolf-Hirschhorn syndrome candidate 1-like 1 WHSC1L1 1.849 down .0167 54904
Fem-1 homolog b (C elegans) FEM1B 1.849 down .0214 10116
Jun oncogene JUN 1.848 down .0243 3725
NDRG family member 2 NDRG2 1.848 down .0415 57447
Protocadherin gamma subfamily A, 1 PCDHGA1 1.847 down .0112 9708
Solute carrier family 6 (neurotransmitter transporter,
creatine), member 8
SLC6A8 1.847 down .0266 6535
Upstream binding transcription factor, RNA polymerase I UBTF 1.847 down .0227 7343
Zer-1 homolog (C elegans) ZER1 1.846 down .0166 10444
Prion protein (p27-30) (Creutzfeldt-Jakob disease,
Gerstmann-Strausler-Scheinker syndrome,
fatal familial insomnia)
PRNP 1.845 down .0168 5621
General transcription factor IIIC, polypeptide 1, alpha 220 kd GTF3C1 1.844 down .0274 2975
Pumilio homolog 1 (Drosophila) PUM1 1.843 down .0257 9698
Splicing factor, arginine/serine-rich 1 (splicing factor 2,
alternate splicing factor)
SFRS1 1.842 down .0158 6426
Kelch repeat and BTB (POZ) domain containing 2 KBTBD2 1.842 down .0124 25948
Translocase of inner mitochondrial membrane
44 homolog (yeast)
TIMM44 1.841 down .0241 10469
1-Acylglycerol-3-phosphate O-acyltransferase 3 AGPAT3 1.841 down .011 56894
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Ezrin EZR 1.840 down .0279 7430
Down syndrome critical region gene 3 DSCR3 1.840 down .0355 10311
v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) ETS1 1.839 down .0347 2113
Ubiquitin-conjugating enzyme E2S///similar
to ubiquitin-conjugating enzyme E2S
(Ubiquitin-conjugating enzyme E2-24 kd)
(Ubiquitin-protein ligase)
(Ubiquitin carrier protein) (E2-EPF5)
LOC731049
///UBE2S
1.839 down .049 27338///
731049
Solute carrier family 6 (neurotransmitter transporter,
creatine), member 8
SLC6A8 1.837 down .0172 6535
Minichromosome maintenance complex component
3 associated protein
MCM3AP 1.835 down .017 8888
Glucocorticoid receptor DNA binding factor 1 GRLF1 1.834 down .0218 2909
Aryl hydrocarbon receptor nuclear translocator ARNT 1.832 down .0179 405
Integrin, alpha 6 ITGA6 1.832 down .0394 3655
La ribonucleoprotein domain family, member 5 LARP5 1.831 down .0238 23185
Heat shock transcription factor 1 HSF1 1.831 down .0255 3297
DCP1 decapping enzyme homolog A (S cerevisiae) DCP1A 1.829 down .0142 55802
Sterile alpha motif domain containing 4A SAMD4A 1.829 down .0121 23034
Desmin DES 1.829 down .0484 1674
KIAA1826 KIAA1826 1.828 down .0423 84437
Microtubule associated serine/threonine kinase family member 4 MAST4 1.828 down .0448 375449
Nuclear factor I/C (CCAAT-binding transcription factor) NFIC 1.828 down .0119 4782
Heat shock 70 kd protein 4 HSPA4 1.828 down .0167 3308
Forkhead box O3 FOXO3 1.827 down .024 2309
Core-binding factor, beta subunit CBFB 1.825 down .0121 865
Mitogen-activated protein kinase kinase 2 MAP2K2 1.822 down .0295 5605
RRN3 RNA polymerase I transcription factor homolog
(S cerevisiae)///RRN3 RNA polymerase I transcription
factor homolog (S cerevisiae) pseudogene
LOC653390///
LOC730092
///RRN3
1.822 down .0307 54700///
653390///
730092
GCN1 general control of amino-acid synthesis
1-like 1 (yeast)
GCN1L1 1.822 down .0242 10985
Cullin 5 CUL5 1.821 down .0119 8065
CDNA FLJ34585 fis, clone KIDNE2008758 1.821 down .0142
Related RAS viral (r-ras) oncogene homolog 2 RRAS2 1.820 down .0206 22800
MAX dimerization protein 4 MXD4 1.820 down .0161 10608
Transglutaminase 2 (C polypeptide,
protein-glutamine-gamma-glutamyltransferase)
TGM2 1.820 down .0419 7052
Collagen, type IV, alpha 1 COL4A1 1.820 down .0216 1282
Polymerase I and transcript release factor PTRF 1.819 down .0286 284119
Methyl-CpG binding domain protein 1 MBD1 1.819 down .0245 4152
BTG family, member 2 BTG2 1.819 down .0337 7832
G protein–coupled receptor kinase 5 GRK5 1.819 down .0452 2869
Protein associated with topoisomerase II homolog 1 (yeast) PATL1 1.818 down .0147 219988
Interleukin enhancer binding factor 3, 90 kd ILF3 1.818 down .0328 3609
Ras homolog gene family, member J RHOJ 1.817 down .0278 57381
Chromosome 10 open reading frame 18 C10orf18 1.817 down .0136 54906
NMDA receptor regulated 2 NARG2 1.817 down .0424 79664
Transcription factor 25 (basic helix-loop-helix) TCF25 1.817 down .0142 22980
Spastic paraplegia 7 (pure and complicated autosomal recessive) SPG7 1.817 down .0368 6687
Heterogeneous nuclear ribonucleoprotein M HNRPM 1.815 down .0206 4670
Fidgetin FIGN 1.814 down .0484 55137
Chromosome 5 open reading frame 41 C5orf41 1.814 down .049 153222
SMAD specific E3 ubiquitin protein ligase 1 SMURF1 1.812 down .0237 57154
Cold inducible RNA binding protein CIRBP 1.812 down .04 1153
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TABLE E2. Continued
Gene title Symbol Fold P value Gene ID
SLAIN motif family, member 2 SLAIN2 1.812 down .0309 57606
Required for meiotic nuclear division 5 homolog
A (S cerevisiae)
RMND5A 1.811 down .0383 64795
SH3 domain protein D19 SH3D19 1.811 down .0445 152503
Pericentriolar material 1 PCM1 1.810 down .00823 5108
Quaking homolog, KH domain RNA binding (mouse) QKI 1.810 down .0266 9444
Insulin-degrading enzyme IDE 1.809 down .0192 3416
zinc finger, HIT type 4 ZNHIT4 1.808 down .018 83444
T-box 5 TBX5 1.808 down .0128 6910
Myeloid/lymphoid or mixed-lineage leukemia
(trithorax homolog, Drosophila); translocated to, 4
MLLT4 1.807 down .0283 4301
Myosin regulatory light chain interacting protein MYLIP 1.807 down .031 29116
Phosphate cytidylyltransferase 1, choline, alpha PCYT1A 1.806 down .0208 5130
RNA binding motif protein 8A RBM8A 1.805 down .0339 9939
Protein kinase C and casein kinase substrate in neurons 2 PACSIN2 1.804 down .0284 11252
Polymerase (RNA) II (DNA directed) polypeptide E, 25 kd POLR2E 1.804 down .0356 5434
Stromal antigen 2 STAG2 1.804 down .0203 10735
Chromosome 1 open reading frame 71 C1orf71 1.803 down .0187 163882
Transmembrane protein 127 TMEM127 1.803 down .0244 55654
Valyl-tRNA synthetase VARS 1.802 down .0291 7407
prosaposin (variant Gaucher disease and variant
metachromatic leukodystrophy)
PSAP 1.801 down .0324 5660
Zinc finger protein 12 ZNF12 1.800 down .0384 7559
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